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Bladder cancer is a health problem that should not be underestimated. The disease 
not only poses a risk for patients, the treatment and follow-up also results in a 
significant burden for the patient. Furthermore, bladder cancer has an impact on 
healthcare infrastructure and on healthcare costs.  
Worldwide, 2.7 million people are estimated to be diagnosed with, or have a history of 
bladder cancer3. Bladder cancer is the second most common genitourinary malignancy 
and overall the sixth leading cause of cancer in the European Union with 124.000 
people being diagnosed and >40 000 people dying from the disease each year4. The 
disease typically is diagnosed in patients over 60 years of age, and occurs three times 
more in men compared to women5, but women tend to present with more advanced 
stage and grade6,7. 
Of all bladder tumours in the Western world, more than 90% are urothelial carcinomas 
(UC). Less common types are squamous cell carcinomas (5%) or adenocarcinomas (2%). 
In this thesis we will only focus on UC. Histological variants of UC (for example 
micropapillary, plasmacytoid, sarcomatoid), although less common, are of growing 
interest, because they have an impact on prognosis, especially for high risk and 
invasive bladder cancer8. 
Of all urothelial carcinomas, the majority (75–85%) present as non-muscle-invasive 
bladder cancer (NMIBC) confined to the mucosa (stage pTa in 70%; carcinoma in situ 
(CIS) in 10%) or to the submucosa (stage pT1 in 20%)9,10. These tumours range from 
relative benign low-risk, low-grade tumours to high-risk, high-grade tumours that will 
almost certainly recur and have a significant risk of progression to muscle-invasive or 
metastatic disease. 
 
2. Risk factors 
Risk factors for bladder cancer include smoking11,12, occupational exposure to 
carcinogens, chronic irritation but also genetic predisposition13-18. Cigarette smoking is 
the strongest known risk factor, with a two- to fourfold increased risk for the 
development of bladder cancer11. Smoking also shortens the time to a recurrence of 
NMIBC12. Carcinogens in cigarette smoke, such as polycyclic aromatic amines, lead to 
increased cell proliferation and DNA damage, resulting in neoplasms. 




In this introduction we will follow the path of a bladder cancer patient, discussing the 
presenting symptoms, diagnostics, operation, pathology, nomograms, treatment and 
follow up. 
 
3. Presentation  
In the majority of the cases, blood in the urine is the presenting symptom of a bladder 
tumour. This blood can be visible (gross haematuria) or microscopically present. In 
daily practice this patient will be referred to the urologist for analysis. With visible 
haematuria, the a priori chance of finding a bladder tumour is as high as 10-24%19-21. 
Microscopic haematuria, on the other hand, is often an incidental finding as part of 
routine examination and has a lower risk of discovering a malignancy: 0 to 8% 
depending on the selection of patients. There are numerous causes for microscopic 
haematuria including a urinary tract infection, kidney disease, urolithiasis, a 
gynaecologic origin, the use of anticoagulants and a malignancy of the urinary tract.  
Sometimes voiding complaints (frequency, urge, irritative symptoms) are the first 
symptoms of a bladder tumour. Together with haematuria, these symptoms are often 
intermittent and are similar to those of benign disorders (urinary tract infection, 
urolithiasis), delaying the diagnosis. It is thought that this delay may account in part 




Figure 1: Cystoscopy of a female patient showing the retroflexed cystoscope (top left, black) at 






When a patient with haematuria is referred to the urologist, cystoscopy is the 
diagnostic standard, combined with urine cytology23,24. Visual assessment with a 
cystoscope is essential for the detection of a malignancy or signs of other causes for 
haematuria such as bladder stones or telangiectasia in case of radiation cystitis.  
Cystoscopy relies on the detection and judgement of the urologist to consider a lesion 
suspicious our unsuspicious. A large bladder tumour will not be missed, but smaller or 
flat lesions can be harder to detect. In case of a suspicious lesion, a successive 
operation is needed to obtain tissue for pathology.  
Urine cytology is useful as an adjunct to cystoscopy, especially if high grade tumours 
are suspected. Positive voided urinary cytology can indicate a urothelial tumour 
anywhere in the urinary tract; negative cytology, however, does not exclude the 
presence of a tumour24. The overall sensitivity is low (34%) ranging from 16% in Grade 1 
and low-grade tumours to 84% in Grade 3 and high-grade tumours25. The specificity, 
however, is around 94%26. There is a number of molecular urinary tests, based on 
cellular and subcellular alterations, associated with bladder cancer including for 
example BTA stat test (Polymedco Inc., Cortlandt Manor, NY,USA), the BTA TRAKR 
test (Polymedco Inc., Cortlandt Manor, NY, USA), Urovysion™ (vysis, Downers Grove, 
IL, USA) and Quanticyt (Gentian Scientific Software, Niawier, The Netherlands)26. In 
initial patient-cohort studies, several markers have shown high specificity and 
sensitivity for low-grade bladder tumours, but successive studies have failed to 
provide comparable results. According to the EAU and AUA guidelines there is 
currently no role for such markers in diagnosis23,24 of bladder cancer and none of these 
tests should replace cystoscopy at this time. 
 
5. Transurethral resection 
A transurethral resection of the bladder tumour (TURBT) will be performed to resect 
all visible tumour, also providing tissue for histopathologic evaluation. 
Although the procedure itself is considered relatively easy, the quality of a TURBT 
varies dramatically between urologists and hospitals, with high recurrence rates at 
first follow-up visit27-29. Tumours present at the resection site within 3 months can 
mostly be considered residual tumours, rather than recurrences. In a large EORTC trial 
with 2410 pTa and pT1 patients, the recurrence rate at first follow-up cystoscopy varied 
between 0 and 45.8%30.  





Resected tissue of suspicious lesions is examined by the pathologist to confirm or rule 
out a malignancy. The pathologist will report several important issues:  
1). The type of tumour and morphology; urothelial carcinoma, variant histology, 
squamous cell carcinoma, adenocarcinoma.  
2). The stage of the tumour according to TNM classification31. Of all urothelial 
carcinomas, 75 to 85% present as non-muscle-invasive bladder cancer (NMIBC) with 
the tumour being confined to the mucosa (stage pTa in 70%; carcinoma in situ (CIS) in 
10%) or to the submucosa (stage T1 in 20%)24. When the tumour invades the detrusor 
muscle (muscle invasive bladder cancer; MIBC) a stage pT2 or higher is reported.  
3). The grade is reported according to the WHO classification32: papillary urothelial 
neoplasm of low malignant potential [PUNLMP], low-grade or high-grade tumours. 
Previously, the 1973 WHO grading system was used, with grade 1 being low-grade, 
grade 3 being high-grade and grade 2 being the ‘default’ grade, accounting for up to 
65% of the NMIBC cases33. In 2004 a new consensus on the grading system was 
published, in an attempt to provide better terminology and to limit interobserver 
variability. The intermediate grade 2 classification was excluded and a new 
classification was defined: PUNLMP 34.  
Carcinoma in situ (CIS) represents a special group of NMIBC since it is a flat lesion, but 
with high malignant potential. When untreated, 54% of CIS patients will progress to 
muscle invasive disease35. CIS can be a condition on its own or it may accompany a 
papillary tumour. CIS can be notoriously difficult to detect.  
Based on pathological characteristics, patients are divided into risk groups24: 
- Low risk tumours: primary, solitary, pTa, low grade or PUNLMP (previous 
Grade 1), size of < 3 cm, and no CIS. 
- Intermediate risk tumours: everything between low- and high-risk tumours. 
- High risk tumours: any of the following: pT1, high-grade (previously grade 3), 
CIS, multiple and recurrent and large pTa tumours. 
 
7. Nomograms 
Owing to the diversity of bladder cancer, it is difficult to establish common treatment 
guidelines. Therefore nomograms are needed, where individuals are classified based 
on tumour parameters (grade, stage, multiplicity, size, recurrence, associated CIS) and 





(molecular) markers will be added to such nomograms. This combined information 
provides data on the risk of recurrence and progression and can guide the choice of 
treatment. The EORTC risk tables, published by Sylvester et al.9, identify tumour 
multiplicity, size and prior recurrence as strong predictors for future recurrence, and 
stage, grade and associated CIS as predictors for progression9. The probabilities for 
recurrence and progression were calculated based on a combined analysis of 2,596 
patients from seven clinical trials. The risk of recurrence after 5 years ranges from 31% 
for low risk to 78% for high risk patients. Progression rarely occurs in low risk patients 
whereas after 5 years up to 45% of the high-risk patients showed progression.  
When considering these EORTC risk tables, it is important to note that the inclusion 
period was 1979–1989, when a postoperative instillation of chemotherapy (§8.2), 
maintenance instillations of chemotherapy (§8.3) and re-resection (§8.1) were not 
standard treatment, but also BCG-treatment was underused (§8.4). According to 
current guidelines, almost all patients were undertreated. Contemporary risks of 
progression and recurrence are therefore lower, as illustrated by the Club Urologico 
Espanol de Tratamiento Oncologico (CUETO) scoring model36, a prediction model for 
intermediate risk patients37, and updated EORTC nomograms for patients treated with 
BCG published in 201538. Despite adjuvant treatment, still the risks of recurrence and 
progression are high. For example, of the high-risk patients treated with BCG, after 5 
years 41% developed a recurrence and 15- 20% showed progression38. Nomograms like 
the EORTC bladder calculator (www.eortc.be/tools/bladdercalculator) and the CUETO 
model (www.aeu.es/Cueto) are capable of generating tailored information, valuable 
for both patient and physician. 
 
8. Disease management and follow up 
Based on the tumour characteristics and nomograms a treatment plan is composed. 
Regardless of adjuvant intravesical therapy, follow up with subsequent outpatient 
cystoscopies is of utmost importance. The frequency and duration of follow up 
cystoscopies depend on the individual risk profile of the patient ranging from a yearly 
evaluation for a total of five years in low-risk bladder cancer, to life-long cystoscopies 









Since accurate staging of the bladder tumour requires detrusor muscle in the resected 
specimen, a re-TURBT is advised when no muscle is present in the tissue. The presence 
of detrusor muscle is a predictor for the recurrence rate at first follow-up visit even 
when the initial TURBT is considered ‘complete’39. The risk of an incomplete resection 
is higher with multiple tumours, high-grade tumours, and increases with stage27. In 
addition, when a tumour was staged pT1 after initial resection, there is understaging 
in 4–10% 40,41 meaning that a considerable proportion of the patients are actually 
diagnosed with muscle invasive bladder cancer. Therefore, the European guidelines 
advocate a re-TURBT in all patients with a pT1 and/or a high-grade tumour24. 
Conversely, a large retrospective study pointed out that in the case of a complete 
resection in pT1 patients, a re-TURBT did not improve clinical parameters such as 
recurrence, progression nor cancer specific survival42.  
Although a (re)TURBT by itself can eradicate a non–muscle invasive bladder 
completely, there is still a considerable chance of recurrence and progression. 
Therefore, adjuvant therapies need to be considered. 
 
8.2. Low risk: single postoperative instillation  
One immediate postoperative instillation of a chemotherapeutic drug (Mitomycin-C or 
Epirubicin) is the recommended adjuvant treatment for patients with low-risk bladder 
cancer, according to the AUA and EAU guidelines23,24. The method of action is thought 
to be twofold: destruction of tumour cells circulating in the bladder immediately after 
TURBT, and chemoablation of residual tumour cells at the resection site. It reduces 
the risk of recurrence with 12–17%43,44. It appears that only patients with a relative low 
risk of progression (EORTC recurrence score <5) or <1 recurrence per year, benefit 
from the single instillation45. In other cases adjuvant treatment is advised.  
 
8.3. Intermediate risk: intravesical chemotherapy or BCG 
Intermediate-risk patients have a high risk of recurrence but a low risk of progression. 
In this category, adjuvant treatment consists of an induction course of intravesical 
instillations of chemotherapy or Bacillus Calmette–Guérin (BCG). Whether or not the 
induction course should be followed by maintenance therapy is a subject of 






8.4. High risk: BCG 
In high-risk patients, the standard choice of adjuvant treatment is an induction course 
of BCG (six weekly instillations) followed by a maintenance schedule of BCG 
instillations23,24.  
Intravesical instillation with BCG consists of the live attenuated form of 
Mycobacterium bovis. Once instilled in the bladder, it causes a complex immune 
response resulting in an antitumour effect. The presumed mechanism of action is 
discussed in §9.1. Various meta-analysis and randomized trials show a reduction in the 
risk for recurrence in favour of BCG maintenance, compared with maintenance 
intravesical chemotherapy or BCG-induction only47,48. Maintenance treatment is 
advised for at least one year, up to three years. Longer treatment might have better 
oncological results, but at the cost of increased side effects. Of all high-risk patients 
treated with BCG, around 41% develops a recurrence and 15-20% progresses to muscle 
invasive bladder cancer38.  
 
8.5. BCG toxicity  
Although BCG is the current standard for the treatment of high risk bladder cancer, 
side effects are very common, resulting in cessation of therapy in 8-19% of patients49,50. 
Most side effects are related to the strong immune response caused by the 
mycobacteria. Local side effects are reported in 63% of patients such as cystitis, 
haematuria, frequency complaints. Systemic side effects occur in one third of the 
patients, with general malaise in 15% and fever in 8% of the patients50. Severe toxicity 
like BCG-sepsis occurs less frequently (0.3%) but can be life threatening50,51. There is an 
extensive list of infrequent but severe side effects including multi-organ granulomata, 
pneumonia and arthritis51.  
 
8.6. Muscle invasive bladder cancer 
When urothelial carcinoma cells invade the detrusor muscle, bladder cancer is 
considered muscle-invasive; stage pT2 and higher23,24,31. In these patients, a radical 
cystectomy is advised by the guidelines, with neo-adjuvant cisplatin-based 
chemotherapy for selected patients. Patients that are unfit for surgery, or when a 
cystectomy cannot be performed due to other reasons, a multimodality treatment 
including re-TURBT, immunotherapy with checkpoint inhibitors, radiotherapy and/or 
chemotherapy needs to be discussed23,24.  




The subject of this thesis is non-muscle invasive bladder cancer, and therefore, the 
diagnostics and treatment of muscle invasive bladder cancer will not further be 
discussed.  
 
8.7. Checkpoint inhibitors 
In recent years, a lot of research is focusing on checkpoint inhibitors as treatment for 
bladder cancer. Initially promising results have been shown for the treatment of 
metastasized and muscle invasive UC, but attention is now also drawn towards (high 
risk) NMIBC. The programmed cell death-1 (PD-1) receptor found on normal cells binds 
to its ligand (PDL-1), inhibiting an immune response and thus acting as a checkpoint. A 
part of the tumour cells present PDL-1 preventing T-cell activation and evading 
antitumour immunity. PD-1 inhibitors (Pembrolizumab, Nivolumab) and PDL-1 
inhibitors (Atezolizumab, Durvalumab, Avelumab) block inhibitory signals, thereby 
enhancing antitumor T-cell immunity 52. Phase II and Phase III trials (for example 
KEYNOTE53, IMVigor54, Checkmate55) demonstrated overall response rates of about 15-
30% in patients who failed platinum based chemotherapy for metastatic urothelial 
carcinoma56. These promising results justify trials of checkpoint inhibitors in localized 
bladder cancer and NMIBC. Results from ongoing trials are to be expected in the near 
future: for example, Atezolizumab (NCT02844816) or Pembrolizumab (NCT02625961) 
in BCG unresponsive patients with NMIBC. Also, the combination of Durvalumab and 
BCG is currently under investigation (NCT03528694). Interestingly, in one trial, the 
intravesical use of Pembrolizumab in recurrent intermediate risk NMIBC is studied 
(NCT03167151). 
 
9. Outline of the thesis  
Despite all adjuvant intravesical therapies with Mitomycin-C or BCG, still the changes 
of recurrence are unacceptably high. Therefore novel treatment strategies for NMIBC 
are needed. The ultimate goal is a treatment for bladder cancer patients that results 
in fewer bladder cancer recurrences with less side effects than the current standard.  
 
In this thesis multiple preclinical experiments and a Phase-1 clinical trial are 
discussed. These studies present novel intravesical immunomodulatory treatments 






9.1. Immunotherapy  
To date, the most efficacious adjuvant intravesical treatment modality is BCG. It is 
already used for more than 40 years and despite numerous clinical studies, all other 
intravesical therapies have proven to be inferior to BCG in reducing bladder cancer 
recurrences and progression57-59. Introduced in 1976, BCG was the first successful 
immunotherapy against cancer60. To date, the exact mechanism of antineoplastic 
activity is still unknown. After intravesical instillation, the mycobacteria initiate 
multiple local immune responses in the bladder wall including cellular infiltration with 
T-cells and macrophages and also induction of local cytokines interleukin (IL)-1, 2, 6, 8, 
12, interferon-γ, Tumour Necrosis Factor (TNF)-α and tumour necrosis factor apoptosis 
inducing ligand (TRAIL)61. The cellular response depends on the Toll Like Receptor 
(TLR) signalling system62. TLR’s are a group of well-conserved transmembrane 
proteins (TLR-1 to 10) expressed on immune cells, normal urothelium and urothelial 
carcinoma63. In BCG-therapy, activation of TLR-2,4 and 9 are involved61,64. 
 
9.2. Imiquimod 
When the antitumor efficacy of immunotherapy is preserved, but the use of live 
mycobacteria is circumvented, one can hypothesize that the aforementioned side 
effects can be reduced.  
In the field of dermatology, the immunomodulator imiquimod is widely used for the 
topical treatment of (pre)malignant skin conditions65,66. Imiquimod activates TLR-7 
resulting in pro-inflammatory cytokines resulting in a strong cellular immune 
response67. Imiquimod also showed to have an inhibitory effect on urothelial 
carcinoma68. In analogy to topical application of imiquimod to the skin, the bladder is 
accessible for local therapy by intravesical instillation.  
 
9.3. Intravesical TLR-7 agonists 
TMX-101, a TLR-7 agonist, is a formulation of imiquimod suitable for intravesical 
instillation. To further improve the immunomodulatory effect of an intravesical 
instillation, a second generation TLR-7 agonist was created. TMX-202 is a stronger 
agonist and has a higher molecule mass compared to TMX-101. To test if this larger 
molecule results in a lower systemic uptake, a preclinical experiment in rats was 
performed. The pharmacodynamic and pharmacokinetic properties of both TMX-101 
and TMX-202 are compared and discussed in Chapter 2.  




The efficacy of both compounds, TMX-101 and TMX-202 was tested and compared to 
a placebo in an orthotopic bladder cancer model in rats. The results of this experiment 
are discussed in Chapter 3.  
 
To establish a safety profile of the investigational drug TMX-101, a phase-1 dose 
escalation study is discussed in Chapter 4. Patients with non-muscle invasive bladder 
cancer were treated with six weekly intravesical instillations of TMX-101 in four 
concentrations starting two weeks after the TUR. The adverse events and 
pharmacokinetic and pharmacodynamic properties were evaluated. 
 
9.4. Curcumin 
In Chapter 5, another immunomodulator is introduced. Curcumin is a component of 
dried turmeric powder; a food spice derived from the plant Curcuma Longa. Curcumin 
is a nontoxic agent, with anti-inflammatory, anti-oxidant and anti-carcinogenic activity 
against urothelial carcinoma. In this chapter, a cyclodextrin-complexed form of 
curcumin is evaluated: first on human and rat urothelial carcinoma cell lines and 
consequently in an orthotopic bladder cancer model in rats. 
 
Chapter 6 provides the general discussion and future perspectives. A summary is 
provided in English in Chapter 7. The Dutch summary (Samenvatting) can be found in 
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Objectives: To evaluate and compare the pharmacokinetic and pharmacodynamic 
properties of two investigational Toll-like receptor 7 agonists, TMX-101 and TMX-202 
after intravenous and intravesical administration in a rat model. TLR-7 agonists are 
successfully used as topical treatment for various (pre)malignant skin lesions and are 
now under investigation as intravesical therapy for non-muscle invasive bladder 
cancer. 
 
Methods: Rats received an intravesical instillation with TMX-101,TMX-202 or vehicle. 
Additionally two groups of rats received an intravenous injection with TMX-101 or TMX-
202. Blood sampling was performed at different time points, including pre-exposure 
and post-exposure to determine the plasma concentrations of study drugs for 
pharmacokinetic and pharmacodynamic analyses and to determine the plasma 
concentrations of cytokines (IL-2, IL-6 and TNF-α).  
Results: We observed no signs of toxicity after intravesical or intravenous 
administration. There was a limited dose dependent systemic uptake of TMX-101 and 
TMX-202 after intravesical administration. The systemic uptake of TMX-202 after 
intravesical instillation was 25 times lower compared to TMX-101.  
 
Conclusions: This in vivo study confirms the safety of intravesical TMX-101 and TMX-
202 administration, with TMX-202 showing lower systemic uptake. TMX-202 has a 
larger molecule-mass compared to TMX-101, and it may therefore have a favourable 
safety profile when treating patients with non-muscle invasive bladder cancer 
intravesically. 





The current treatment of non-muscle invasive bladder cancer (NMIBC) is suboptimal 
as demonstrated by recurrence rates of up to 78% after five years1. European and 
American Guidelines recommend transurethral resection of the bladder tumor 
followed by adjuvant intravesical treatment for intermediate and high-risk patients1,2. 
Nevertheless, even after adjuvant treatment with intravesical Bacillus Calmette-
Guérin (BCG), the risk of recurrence after five years is as high as 41.3%3. Because of 
these modest results, new treatment options are needed.  
The Toll-Like-Receptor(TLR) family (TLR-1 to TLR-10) is a conserved group of 
transmembrane proteins playing a pivotal role in innate- and adaptive immunity4,5. TLR 
activation leads to a coordinated immune response culminating in antigen 
presentation by mature dendritic cells and enhanced production of antigen specific T-
cells4,6-8. On top of activation of innate immunity against pathogens, the involvement 
of TLR in antitumor immunity has been shown9. Indeed, the success of BCG therapy 
for urothelial carcinoma (UC) is (partly) based on TLR-activation6,7,10,11. 
Imiquimod, a synthetic TLR-7 agonist, is used as first line topical treatment for benign 
and malignant skin lesions12,13 including genital condylomas and penile carcinoma in 
situ14. Imidazoquinolines like imiquimod also have a direct effect on UC6 and may 
therefore represent an alternative intravesical treatment moiety against UC.  
TMX-101 is an imiquimod formulation, suitable for intravesical instillation15,16. 
Preclinical15 and early-phase clinical trials17-19 have convincingly demonstrated the 
safety of TMX-101. TMX-202 consists of a TLR-7 ligand conjugated to a phospholipid. It 
is a highly specific agonist of TLR-7 and in in vitro cellular essays, proinflammatory 
cytokine levels are approximately two-fold higher compared to imiquimod20,21. Our aim 
was to evaluate and compare the pharmacokinetic and pharmacodynamic behavior of 
the investigational drugs TMX-101 and TMX-202 in the Fischer F344-rat after 
intravesical and intravenous administration.  
 
2. Material and methods 
2.1. TLR-7 expression  
To determine TLR-7 expression in F344-rat tissue we isolated RNA from F344 rat 
bladder samples (n=3), bladder without urothelial layer (n=1), prostate (n=1), and 
spleen (n=2) for reverse transcription-polymerase chain reaction (RT-PCR) analysis 





(intron spanning), Tlr7-rat-reverse TACCATCGAAACCCAAGGAC, as control gene 
GAPDH was used. Primers GAPDH forward ATGGGAAGCTGGTCATCAAC, GAPDH 
reverse GGATGCAGGGATGATGTTCT.  
 
2.2. Animals 
Animal protocols were approved by the Institutional Animal Care and Use Committee, 
Committee for Animal Experiments (Radboud University Nijmegen Medical Centre, 
The Netherlands) and were in compliance with Dutch and European regulations (EU-
Directive 2010/63/EU). Forty-two female Fischer F344-rats (Charles River, L’Arbresle 
Cedex, France) were housed for two weeks before the experiment. The rats, age 9-11 
weeks, weighing 170g ± 10g, were housed in cages (Techniplast, Milan, Italy) with 
goldflake bedding (SPPS, Frasne, France) in a temperature controlled environment 
with a 12-hour light/dark cycle with free access to chow and water. Daily, the rats were 
weighed and monitored for wellbeing. The sample size of six rats per group was 
chosen to collect adequate volumes of blood samples and minimize the risk of 
confounding variability between the rats. F344-rats were chosen because for future 




The following agents were used for intravesical instillation: TMX-101, 2.08 mM(0.05%) 
and 4.16 mM(0.1%), a formulation of imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-
c]quinolin-4-amine). TMX-202 (2-(4-((6-Amino-2-(2-methoxyethoxy)-8-oxo-7H-purin-
9(8H)-yl) methyl) benzamido) ethyl 2,3-Bis (dodecanoyloxy) propyl phosphate), in two 
concentrations: 2.08 mM(0.19%) and 4.16 mM(0.38%). The solutions were sterile and 
dissolved in 0.1 M lactic acid, 16% poloxamer-407 and 5% hydroxypropyl-
betacyclodextrin vehicle. For intravenous administration sterile solutions of TMX-101 
6.24 mM(0.15%) in 5% hydroxypropyl-betacyclodextrin and TMX-202 6.24 mM(0.56%) in 
5% hydroxypropyl-betacyclodextrin were used. Agents were provided by Telormedix, 
S.A.. Intravesical TMX-101 was subject of multiple clinical trials17-19 and further 
developed under the brand name Vesimune by UroGen Pharma. 
Drug concentrations for intravesical administration were within the expected clinical 
significant range. As safety margin, 1.5 times the highest concentration of intravesical 
administration was used as concentration for intravenous administration. 





2.4. Experimental design 
Experiments were performed under inhalation anaesthesia (isoflurane 2%, nitric oxide 
0.5 L/min and oxygen 1 L/min). Rats were randomly assigned to one of seven 
experimental groups. Five groups of six rats received an intravesical instillation with 
0.5mL TMX-101 and TMX-202 at two concentrations, or vehicle (Table 1). The bladder 
was transurethrally catheterized with a 16-gauge intravenous cannula (BD Biosystems, 
Erembodegem-Aalst, Belgium) and drained before instillation with 0.5mL drug or 
vehicle. To resemble the clinical situation, an indwelling time of one hour was used. 
Blood samples were collected before and 15, 30, 60, 120 and 480 minutes after drug 
instillation. Furthermore, two groups of six rats received an intravenous injection of 
0.2 mL 6.24 mM TMX-101 or TMX-202 (0.3 mg (1.76 mg/kg) and 1.12 mg (6.59 mg/kg) 
respectively) and blood samples were taken before administration and after 5, 15, 30, 
60, 120 and 240 minutes. At the first two time points, blood was withdrawn from all 
rats. For other time points an alternating scheme was used to diminish the risk of 
animal loss, leading to four blood samples per rat. Per time point blood samples were 
taken from at least three rats within a treatment group. 
Twenty-four hours after administration, rats were weighed, anesthetized and 
sacrificed after blood sampling, using CO2 inhalation. Bladders were removed, 
weighed, fixed in formalin 4%, (Boom B.V., Meppel, The Netherlands), laminated and 
embedded in paraffin for histopathological analysis by H&E staining. A specialized 
uropathologist assessed the degree of inflammation and abnormalities. Bloodsamples 
were collected in Microvette 500 µl lithium-heparin-gel tubes (Sarstedt, Nümbrecht, 
Germany), immediately stored on ice and processed within 30 minutes. Samples were 
centrifuged at 4˚C for 15 minutes at 3,200 rpm. Plasma was stored at -80°C.  
Table 1: Experimental groups and corresponding treatments. 
Group  Treatment Dosage Route N= 
1 TMX-101  2.08 mM (0.05%), 0.5 mL Intravesical 6 
2 TMX-101  4.16 mM (0.1%), 0.5 mL Intravesical 6 
3 TMX-202  2.08 mM (0.19%), 0.5 mL Intravesical 6 
4 TMX-202  4.16 mM (0.38%), 0.5 mL Intravesical 6 
5 Vehicle control 0.5 mL Intravesical 6 
6 TMX-101  6.24 mM (0.15%), 0.2 mL Intravenous 6 





2.5. Sample analysis 
Plasma concentrations of imiquimod and 2-(4-((6-Amino-2-(2-methoxyethoxy)-8-oxo-
7H-purin-9(8H)-yl) methyl)benzamido)ethyl 2,3-Bis (dodecanoyloxy) propyl 
phosphate (TMX-202) were analysed by Nikem Research (Baranzate, Italy) using liquid 
chromatography-mass spectroscopy/mass spectroscopy. In a Sirocco Filter Plate 
(Waters Corp. Milford, Massachusetts, USA), 50 µl of plasma was added to 195 µl of 
ACN/MeOH 1:1, spiked with 5 µl of IS. After shaking for 10 minutes, the plate was 
filtered under vacuum (5-10 mmHg). LC/MS/MS was performed with a Quattro 
Premiere XE spectrometer (Waters Corp. Milford, Massachusetts, USA), Column: 
Acquity BEH C8 50x2.1 mm 1.7 um, and MeOH/H2O 95/5(A) + 0.1% HCOOH,5/95 (B) as 
eluent. Concentrations of interleukins(IL)-6, IL-2 and Tumour Necrosis Factor (TNF)-α) 
were determined using the Fluorokine MAP multiplex kit (R&D Systems Inc., 
Minneapolis, USA).  
 
2.6. Data analysis  
The data was analysed using GraphPad Prism 5.03(GraphPad Software Inc, USA). Area 
under the Curve (AUC) was calculated with GraphPad Prism. Groups were analysed 
using one-way ANOVA. For comparing two values t-test was used. P<0.05 was 
considered significant.  
 
3. Results 
One rat (vehicle group) died during intravesical treatment under anaesthesia. 
Postmortem examination showed an intact bladder and no abnormalities of other 
organs. No abnormal cytokine plasma levels were measured in this rat. All other rats 
were included in the study. Adverse events, including weight loss, were not observed 
and animals did not show signs of impaired wellbeing (e.g. activity, condition and 
haematuria). At post-mortem inspection, no abnormalities of the bladder or other 
internal organs were detected. H&E stained sections of all rat bladders were evaluated 
by a uropathologist (CHvdK). Instillation with TMX-101 or TMX-202 did not lead to any 
morphological changes and no signs of an increased number of inflammatory cells (i.e. 








3.1. TLR-7 Expression 
To examine TLR-7 expression in urothelial cells, reverse transcription-polymerase 
chain reaction was performed on F344 rat urothelium, prostate and spleen. This 
showed unequivocal expression of TLR-7 expression in all tissues examined. PCR 




Figure 1: RT-PCR of various F344 rat tissues using TLR-7 specific primers. Lane 1: 100bP marker, 
2: spleen, 3: spleen, 4: bladder, 5 prostate, 6 bladder, 7 bladder, 8 bladder (no epithelial layer).  
 
 
3.2. Drug plasma levels after intravesical instillation 
After instillation of 2.08 mM TMX-101, imiquimod plasma levels rapidly increased to a 
maximum concentration (Cmax) of 3.27 ng/mL (0.014 µM) 30 minutes after start of the 
instillation. Thereafter the imiquimod plasma levels declined to undetectable levels at 
4 hours. Similarly, a rapid increase of TMX-101 levels was observed after instillation of 
4.16 mM TMX-101. However, the Cmax level was much higher (9.13 ng/mL, 0.038 µM) 
and Cmax was reached later (1 hour versus 30 minutes). After Cmax was reached the 
imiquimod plasma levels decreased to undetectable levels eight hours after start of 
the installation (Figure 2A and Table 2). 
Instillation of the equimolar amount of TMX-202 (4.16 mM) also resulted in an increase 
of TMX-202 levels, with Cmax reached 1 hour post initiation of treatment. However, the 





to TMX-101 (One-way ANOVA, p =0.0026). At all other time points TMX-202 plasma 
levels were below the limit of detection. After instillation of 2.08mM TMX-202, the 
drug could not be detected in the plasma at any time point.  
The AUC was calculated to determine drug exposure after TMX-101 and TMX-202 
instillation at different doses. Since TMX-202 was undetectable at the lowest dose 
tested (2.08 mM), we assume that the level of systemic drug exposure was very 
limited. Intravesical instillation of 2.08 and 4.16mM TMX-101 resulted in systemic 
imiquimod exposure of 9.43 and 28.40 ng*hr/mL respectively. The AUC for instillation 
of TMX-202 at the highest dose tested (4.16mM, Table 2) was 0.30 ng*hr/mL.  
 
Table 2: Pharmacokinetic parameters of TMX-101 and TMX-202 after intravesical and 
intravenous administration.  






1 TMX-101, 2.08 mM Intravesical 3.27 30 9.43 
2 TMX-101, 4.16 mM Intravesical 9.13 60 28.40 
3 TMX-202, 2.08 mM Intravesical <LLOQ - - 
4 TMX-202, 4.16 mM Intravesical 0.36  60 0.30 
6 TMX-101, 6.24 mM Intravenous 729.50 5 473.87 
7 TMX-202, 6.24 mM Intravenous 9178.11 5 2458.18 
Cmax= maximum concentration, Tmax = time point of maximum concentration, AUC = Area 
under the curve, LLOQ=lower limit of quantification. 
 
 
3.3. Drug plasma levels after intravenous administration  
Five minutes after infusion (p.i.), of TMX-101 and TMX-202, Cmax was 729.50 ng/mL(3.04 
µM) and 9178.11 ng/mL(10.05 µM) for imiquimod and TMX-202 respectively. Because 
TMX-101 has a molecule mass that is 3.8 times lower compared to TMX-202 it is possible 
that a larger fraction of the drug was already been cleared from the plasma 5 minutes 
p.i.. Both drugs showed a biphasic clearance pattern with rapid clearance during the 
first 30 minutes. T1/2-alpha and T1/2-beta were calculated to be 6.4 and 139 minutes 
after IV-bolus of TMX-101 versus 3.1 and 26 minutes after IV-bolus of TMX-202 (Figure 
2B). After 24 hours, plasma levels were undetectable. The calculated AUC for 
imiquimod and TMX-202 after intravenous administration were 473 and 2458 
ng*hr/mL respectively (Table 2). 




3.4. Cytokine levels after intravesical instillation 
Intravesical instillation of TMX-101 and TMX-202 caused a rise in IL-6 levels which 
peaked at 120 minutes after start of the instillation (131-361 pg/mL), see Figure 3A. 
Although the difference in plasma concentrations between TMX-101 and TMX-202 
after intravesical instillation was substantial, the plasma IL-6 levels did not differ 
between treatment- and vehicle groups at any time point (One-way ANOVA, p=0.90). 
IL-2 levels were below the lower limit of quantification (LLOQ) in all samples. 
For TNF-α, the intergroup and intragroup variance was high, see Figure 3B. The two 
TMX-101 groups showed increased levels of TNF-α at baseline: 29.4 pg/mL and 26.9 
pg/mL for group 1 (TMX-101, 2.08 mM) and 2 (TMX-101, 4.16 mM) respectively (One-
way ANOVA, p<0.001). The TNF-α levels returned to lower levels between 480 minutes 
to 24h after instillation. TNF-α levels of rats in groups 3 (TMX-202, 2.08 mM), 4 (TMX-
202, 4.16 mM) and 5 (vehicle-control) increased slightly after instillation, with 
maximum levels of 3.5 pg/mL. The difference between treated- and vehicle groups 





Figure 2: A: Rat plasma concentration of TMX-101 and TMX-202 after intravesical 
administration of 0,5mL TMX-101 or TMX-202 at concentrations of 2.08mM or 4.16mM. Plasma 
concentrations of TMX-202 are significantly lower compared to TMX-101 (p=0.0026, One-way-
ANOVA). B: Rat plasma concentration of TMX-101 and TMX-202 after intravenous 
administration of 0.2mL TMX-101 or TMX-202 at concentration of 6.24mM. Plasma 
concentrations represent an average of three animals per time point. Plasma levels in ng/mL, 









Figure 3: Rat plasma concentrations of IL-6 (A.) and TNF-α (B.) after intravesical administration 
of 0,5mL TMX-101 or TMX-202 at concentrations of 2.08mM or 4.16mM. The IL-6 concentration 
(A). did not differ between study groups (One-way ANOVA, p=0.90). The TNF-α concentration 
(B.) was significantly higher for the TMX-101 treated groups, from baseline to time point 480 
minutes (One-way ANOVA, p<0.001). Plasma concentrations represent an average of three 
animals per time point. Plasma levels in ng/mL, time in minutes and error bars representing 





Figure 4: Rat plasma concentrations of IL-6 (A.) and TNF-α (B.) after intravenous 
administration of 0,2mL TMX-101 or TMX-202 at concentration of 6.24mM. Maximum 
concentration of IL-6 are comparable between groups (T-test p=0.35), whereas maximum 
concentration of TNF-α after TMX-202 administration is significantly higher (T-test p=0.033)  
Plasma concentrations represent an average of three animals per time point. Plasma levels in 








3.5. Cytokine levels after intravenous administration 
Intravenous administration of TMX-101 and TMX-202 caused a sharp rise in IL-6 plasma 
concentrations with a Cmax of 675.4 pg/mL for TMX-101, and 859.6 pg/mL for TMX-202 
(p=0.35) at 120 minutes, see Figure 4A. TNF-α levels were reached after 60 minutes and 
were 73.2 pg/mL and 566.7 pg/mL for TMX-101 and TMX-202 respectively, (p=0.033) 
(Figure 4B). IL-2 levels were below lower limit of quantification. 
 
4. Discussion 
In this preclinical pharmacokinetic and pharmacodynamic study we demonstrate that 
systemic uptake of TMX-101 and TMX-202 was dose dependent with the highest drug 
peak levels reached 60 minutes postinstillation. Systemic plasma levels of TMX-202 
were approximately 25 times lower compared to imiquimod and close to the lower 
limit of detection. Both drugs exhibited a favourable safety profile with moderate 
cytokine peak levels 2 hours post-instillation that rapidly declined to normal levels. 
In analogy to the topical administration of imiquimod-cream (Aldaratm) for skin 
malignancies12-14,23,24, local treatment of bladder cancer may be possible by intravesical 
instillation of the TLR-7 agonists TMX-101 or TMX-202. TLR-7 is expressed in human, pig, 
mouse6,15 and F344 rat urothelium. TLR-7 activation via the myeloid differentiation 
primary response protein-88 (MyD-88) dependent pathway9 leads to activation of 
transcription factors like nuclear factor κ-B, the induction of several proinflammatory 
cytokines, chemokines and interferons (IFN’s) and the recruitment of activated 
dendritic cells, monocytes and macrophages6,8,10. The net effect of this cascade of 
events is a cell-mediated anti-tumour response. Additionally, imiquimod has also a 
direct pro-apoptotic effect on tumour cells6,10, including UC6,16. 
 
Previous preclinical studies demonstrated the safety and efficacy of imiquimod (TLR7 
agonist) as treatment for UC6,15,16. TMX-202, a TLR-7 ligand conjugated to a 
phospholipid carrying two saturated alkyl chains of 12 carbon atoms each (2-(4-((6-
amino-2-(2-methoxyethoxy)-8-oxo-7H-purin-9(8H)-yl) methyl)benzamido)ethyl 2,3-bis 
(dodecanoyloxy) propyl phosphate), was expected to be released more slowly into 
the systemic circulation due to its larger molecular mass and lipophobicity. Moreover, 
the conjugation of the TLR-7 agonist to phospholipids facilitates the uptake by 
endocytosis20 and compared to imiquimod stronger local immunostimulatory 





Consequently, a prolonged local immunostimulatory response compared to TMX-101 
is anticipated, combined with lower systemic exposure. Indeed, TMX-202 plasma 
levels were much lower than TMX-101 plasma levels after intravesical instillation. At 
the lowest dose tested, TMX-101 plasma rapidly increased and Cmax was reached after 
30 minutes while TMX-101 was still indwelling, indicating a steady state between 
systemic release and clearance from the plasma, whereas TMX-202 was below the 
level of detection. At the highest concentration of TMX-101 and TMX-202 tested, both 
drugs were measurable in the plasma with the maximum plasma levels reached after 
60 minutes and steady state between systemic release and clearance was not yet 
achieved. After cessation of intravesical exposure, the study drugs were rapidly 
cleared from the plasma. Thus, the higher molecular mass of TMX-202 and the 
phospholipidic conjugation lead to a pharmacokinetic behaviour that considerably 
differs from TMX-101. The fact that the systemic uptake of TMX-202 is substantially 
lower compared to equimolar doses of TMX-101 suggests that intravesical instillation 
with TMX-202 potentially has less systemic side effects when treating patients for 
NMIBC. 
 
Although systemic TMX-101 and TMX-202 plasma levels were measurable, systemic IL-
6 levels did not differ between vehicle and treatment groups. Elevated plasma IL-6 
levels were present, but these were most likely owing to experimental procedures 
(e.g. anaesthesia). Similarly, baseline TNF-α plasma levels were elevated in two study 
groups, unrelated to the study drugs. Apparently, the plasma concentrations of the 
study drugs were too low to exert a significant systemic cytokine release. This is in 
agreement with a dermatologic study comparing topical administration of imiquimod 
to TMX-202: Here they demonstrated that TMX-202 had greater immunostimulatory 
effect in vitro, but a less systemic release of IL-6 and TNF-α in vivo21. In the absence of 
a measurable systemic response, a local cytokine response, detected in urine or tissue, 
may reveal the difference in agonist potential between TMX-101 and TMX-202 in vivo. 
Unfortunately, we did not measure the urinary cytokines after instillation, since the 
quantities of voided urine were insufficient. Urinary cytokines may be of interest in 
future studies, since they may predict a treatment effect25. Histological evaluation did 
not reveal signs of an inflammatory response. However, rats were sacrificed after 24 
hours, and this may have been too early to observe the cellular influx. Intravenous 
administration did not lead to side-effects in the rats.  




In both groups, a systemic cytokine response was observed with IL-6 peaking at 120 
minutes and TNF-α peaking at 60 minutes after intravenous administration. This 
indicates that both drugs function as a TLR-7 agonist, albeit that significant higher 
levels of TNF-α were observed in the TMX-202 group compared to the TMX-101 group, 
indicating that TMX-202 is a superior TLR-7 agonist20.  
 
In a phase-1 dose-escalation study17 and a marker-lesion study of intravesical 
administered imiquimod in patients with NMIBC18, six instillations of TMX-101 did not 
result in an ablative effect on a marker lesion in seven patients with low-grade UC. 
More recently, a complete response in two of ten CIS patients, six weeks after six 
instillations of TMX-101 has been described19. All three clinical trials showed a good 
safety profile of 2.08-16.64 mM (0.05-0.4%) TMX-101 with low systemic uptake. 
Nevertheless, side effects were observed in almost all patients, mostly confined to the 
genitourinary tract. The Cmax was 3.14 and 1.64 ng/mL in humans17 versus 3.27 and 9.12 
ng/mL in rats after instillation of 0.05% and 0.1% TMX-101 respectively. Because the 
instilled-volume/body-weight ratio of rats is higher compared to humans (0,5 
mL/0.17kg vs. 50 mL/70kg) the relative exposed bladder surface is higher, explaining 
the higher plasma levels in rats.  
 
5. Conclusions 
In this in vivo study, we confirm the safety of TMX-101 and TMX-202 after both 
intravesical and intravenous administration. After intravesical instillation, there was a 
dose dependent systemic uptake that was remarkably lower for TMX-202 compared 
to TMX-101. TMX-202 is a potent TLR-7 agonist and has a larger molecule-mass, and it 
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Purpose: TMX-101 and TMX-202 are formulations of toll-like receptor 7 (TLR-7) 
agonists, under investigation for the treatment of urothelial carcinoma. Our goal was 
to evaluate the efficacy of intravesical instillations of TMX-101 or TMX-202 in an 
orthotopic bladder cancer rat model. 
Methods: Four groups of 14 rats received an instillation with isogenic AY-27 tumour 
cells on day 0, starting tumour development. On day 2 and 5, the rats were treated 
with an intravesical instillation of TMX-101 0.1%, TMX-202 0.38%, vehicle solution or 
NaCl. On day 12 the rats were sacrificed and the bladders were evaluated 
histopathologically. 
 
Results: No signs of toxicity were seen. The number of tumour-positive rats was 11 of 
14 (79%) in the vehicle control group and in the NaCl control group, versus 9 of 14 (64%) 
in the TMX-101-treated group, and 8 of 14 (57%) in the TMX-202-treated group. The 
difference between tumour-bearing rats in the treated and control groups was not 
significant (p = 0.12). Bladder weight was significantly lower for TMX-202-treated rats 
compared to vehicle (p = 0.005). 
 
Conclusions: TMX-101 and TMX-202 are TLR-7 agonists with antitumor activity. 
Treatment with TMX-101 and TMX-202 resulted in less tumour-bearing rats compared 
to vehicle or saline control groups, although not statistically significant. In this 
aggressive bladder cancer model, a lower number of tumour-positive rats after 
treatment with TLR-7 agonists indicates activity for the treatment of non-muscle 









At any point in time 2.7 million people have a history of urothelial bladder cancer 
worldwide1. Of the newly diagnosed cases, around 70% is non-muscle invasive bladder 
cancer (NMIBC)2.  
After transurethral resection of the bladder tumour (TURBT), for high risk patients an 
adjuvant treatment with intravesical bacillus Calmette-Guerin (BCG) is 
recommended2,3. BCG was the first successful immunotherapy for cancer and has 
been used for over 40 years to reduce the risk of bladder cancer recurrence as well as 
the risk of progression to muscle invasive disease.  
Intravesical instillation of BCG induces a complex immune response leading to a Th-1 
cell-mediated immune response responsible for cytotoxic T-cell activity against 
urothelial carcinoma (UC)4. This cellular response depends on the Toll-like receptor 
(TLR) signalling system5. TLR’s are a group of transmembrane proteins (TLR-1 to 10) 
expressed on immune cells, normal urothelium and urothelial carcinoma (UC)6. In BCG-
therapy, activation of TLR-2,4 and 9 are involved4,7. 
Despite being the gold-standard for adjuvant treatment, the 5-year recurrence rate is 
41% in NMIBC patients treated with BCG for 1-3 years8. In addition, side effects of BCG 
therapy may occur, ranging from mild local complaints in half of the patients, to severe 
systemic adverse effects, leading to cessation of treatment. Due to the modest 
success of the current treatments, new treatment options are under investigation.  
The role of TLR’s in the antitumor activity of BCG supports further research on direct 
activation of TLR’s as potential therapy for UC. The immunomodulator imiquimod is a 
TLR-7 agonist widely used for the topical treatment of genital warts and 
(pre)malignant skin conditions9,10. Application of imiquimod leads to induction of pro-
inflammatory cytokines, and thereby to a strong antitumor cellular immune response 
via the MyD88-dependant pathway11. The therapeutic role of imiquimod may not be 
limited to the skin; studies show an inhibitory effect of imiquimod on UC12. To permit 
intravesical instillation of imiquimod, TMX-101 was developed. It shows an antitumor 
effect on bladder cancer cells, in vitro and in vivo13,14 and it has been tested for 
pharmacodynamics and pharmacokinetic in pigs15 and rats16, showing a good safety 
profile. Three clinical trials confirmed the safety and tolerability of TMX-10117-19. TMX-
202 is a highly specific agonist of TLR-7, which in in vitro cellular assays shows about 






Recently, we compared the pharmacokinetic and pharmacodynamic properties of 
TMX-202 and TMX-101 in the same F344 rat model showing a significant lower systemic 
uptake of TMX-202 compared to TMX-101 after intravesical administration of 
equimolar dose16. It may, therefore, have a better safety profile compared to TMX-101. 
The goal of this study was to evaluate the efficacy of TMX-101 and TMX-202 compared 
to vehicle and saline in an orthotopic bladder cancer rat model.  
 
2. Materials and methods 
2.1. Tumour cells 
The AY-27 rat bladder cancer cell-line was established from a primary bladder tumour 
in N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide fed Fischer F344 rats. After thawing of 
the cells, they were passaged six times to revitalize the cells. Eventual passage 
numbers were 28 or 29. The cells were cultured as a monolayer in RPMI-1640 medium 
with L-glutamine (Invitrogen, Carlsbad, California), supplemented with 10% foetal calf 
serum (Sigma-Aldrich, St. Louis, MO), 100 U/mL penicillin-G and 100 μg/mL 
streptomycin (Invitrogen, Carlsbad, California) in a humidified 95% air / 5% CO2-
atmosphere. Medium was replaced two times a week, and when confluent, cells were 
split with standard trypsinisation procedures. 
 
2.2. Animals 
A total of 56 female Fischer F344 rats (Charles River, L’Arbresle Cedex, France) were 
acclimatized for at least one week before start of the experiments. The rats, weighing 
170 ±10g, were housed in cages (Techniplast, Milan, Italy) with goldflakes bedding 
(SPPS, Frasne, France) and environmental enrichment, in a temperature-controlled 
environment with a 12-hour light/dark cycle. Rats had free access to standard chow 
and water. Daily, the rats were weighed and monitored for wellbeing. Animal 
procedures were performed according to protocols, approved by the Institutional 
Animal Care and Use Committee (IACUC), Committee for Animal Experiments 
(Radboud University Nijmegen Medical Centre, The Netherlands) and were in 
compliance with Dutch and European regulations. Group size was calculated using an 
α of 0.05, a power of 80 and 80% tumour development. The expected therapy effect 
was estimated to be 50% considering a pathological complete response (pT0) as 
primary endpoint. This resulted in a minimal group size of 14 rats.  
 




2.3. Tumour cell implantation 
Tumour cell implantation was performed according to the protocol described by Xiao 
et al.21. Enrofloxacin (Bayer, Leverkusen, Germany) (5-10 mg/kg) was injected 
subcutaneously before catheterization. Experiments were performed under 
inhalation anaesthesia: isoflurane 2-5% (induction), followed by Isoflurane 2%, nitric 
oxide 0.5 L/min and oxygen 1 L/min. The bladder was catheterized via the urethra with 
a 16-gauge intravenous cannula (BD Biosystems, Erembodegem-Aalst, Belgium) and 
drained. The bladder was pre-conditioned with an instillation of 0.4 mL 0.1 M 
hydrochloride for 15 s and neutralized by adding 0.4 mL 0.1 M potassium hydroxide for 
again 15 s. The bladder was drained and flushed 3 times with 0.8 mL 0.01 M PBS. Within 
30 min after harvesting, 1.5x106 cells, resuspended in 0,5 mL medium, were instilled in 
the rat-bladder and left indwelling. After 1 h, the catheter was removed, and the rats 
could void spontaneously.  
 
2.4. Treatment 
All rats received an intravesical instillation on day 2 and 5. The rats were anesthetized 
as described before. Subsequently, the rats were catheterized via the urethra, the 
bladder was drained and the pH was measured (pH indicator strips, Merck Milipore, 
Massachusetts, USA). Then, 0.5mL instillation was administrated intravesically. Group 
1 was treated with TMX-101 0.1% (4.16 mM). Group 2 was treated with TMX-202 0.38% 
(4.16 mM). Group 3 received an instillation with the vehicle (0.1 M lactic acid, 
poloxamer-407 16% and hydroxypropyl-β-cyclodextrin 5%) and group 4 received an 
instillation with NaCl as a control. Study drugs were provided by Telormedix SA 
(Switzerland), now part of UroGen Pharma Ltd. (Ra’anana, Israel). The instillation 
remained in the bladder for 1 h. After removal of the catheter, the pH of spontaneously 
voided urine was measured using pH-indicator strips. 
 
2.5. Pathological evaluation 
On day 12, the rats were sacrificed using CO2 inhalation. At necropsy the internal 
organs were inspected and cystectomy was performed. The bladders were weighed, 
fixated using 4% buffered formalin (Boom B.V. Meppel, The Netherlands), laminated 
and embedded in paraffin. Sections of 5 μm were stained using haematoxylin and 
eosin (H&E). A specialized uro-pathologist (C.H.K.) blinded to the treatment groups, 





tumour grade according to the 2004 WHO/ISUP classification. The invasion depth of 
the tumours was measured. The amount of inflammation in the bladder wall and/or 
surrounding tissue was scored 0 (no inflammation), 1 (mild), 2 (moderate) and 3 
(severe inflammation). Data were analysed using SPSS Statistics, Version 21.0 (IBM 
Corp., Armonk, USA). Graphs were created using GraphPad Prism 5.03(GraphPad 
Software Inc, USA).  
 
3. Results 
During the experiment, there were no signs of impaired well-being of the rats. Mild 
haematuria on the day of catheterization was observed occasionally but on 
subsequent days, the urine returned normal. The pH of the urine before and after 
treatment showed no difference; the pH of all urines varied between 6.5 and 7.0. At 
necropsy no abnormalities to internal organs other than the bladder were seen. At 
macroscopic evaluation tumour positive bladders appeared to have tumour mass 
without extravesical growth. Only one rat bladder (vehicle treated) showed a mass 
near the right ureteral orifice, extending towards the right ureter. 
 
3.1. Bladder weight 
The bladder weight, a substitute for tumour load, is shown in Table 1. There was clear 
correlation between bladder weight and the presence of tumour (p<0.0001, 
independent samples T-test). The mean bladder weight of the TMX-202 treated 
animals was significantly lower compared to the vehicle group (p=0.005, independent 
samples T-test). No difference in mean bladder weight was seen between other 
groups. In Fig. 1, a boxplot shows the bladder weight per treatment group. 
 
Figure 1: Boxplot showing the bladder weight in grams. Whiskers represent min. and max. 
values. 




Table 1: Mean weight of the rat bladders per treatment group. Weight in grams. 




Yes (n=9) 0.137 0.032 
No (n=5) 0.089 0.008 
All 0.120 0.035 
TMX-202 
Yes (n=8) 0.114 0.022 
No (n=6) 0.084 0.005 
All 0.101 0.023 
Vehicle 
Yes (n=11) 0.162 0.030 
No (n=3) 0.090 0.003 
All 0.144 0.042 
NaCl 
Yes (n=11) 0.114 0.023 
No (n=3) 0.088 0.004 
All 0.108 0.023 
All 
Yes (n=39) 0.132 0.033 
No (n=17) 0.088 0.006 




In almost all rat-bladders, a certain degree of inflammation was present, showing 
infiltrating lymphocytes. Between groups no statistically significant difference was 
observed (p=0.106, Pearson’s Chi-square test). The mild and moderate degree of 
inflammation accounted for 87.5% of all 56 cases.  
 
3.3. Tumours and tumour response 
The percentage of rats with urothelial carcinoma of the bladder was 64.3% (9/14) for 
the TMX-101 treated group, 57.1% (8/ 14) for the TMX-202 treated group, 78.6% (11/14) 
for the vehicle-control group and also 78.6% (11/14) for the NaCl control group, see 
Table 2. In total 69.6 % (39/56) of the rats were tumour positive. All tumours show a 
pT2 stage, except one pTa tumour in a TMX-202 treated rat. The difference between 
tumour negative rats in the treated and control groups was not statistically significant 
(p=0.12 Fischer’s exact test). There was no significant difference between the 





The treatment given was not predictive of the outcome (tumour positive versus 
tumour negative), when a logistic regression analysis was performed on the data; 
additional data on the logistic regression analysis can be found in online resource 1 , 
DOI: 10.1007/s00345-018-2334-3. 
 
Table 2: Number of rats with urothelial carcinoma of the bladder, per treatment group.  
Treatment group Tumourfree pTa pT2 Total 
TMX-101 5 (35.7%)  9 (64.3%) 14 (100%) 
TMX-202 6 (42.9%) 1 (7.1%) 7 (50.0%) 14 (100%) 
Vehicle 3 (21.4%)  11 (78.6%) 14 (100%) 
NaCl 3 (21.4%)  11 (78.6%) 14 (100%) 
pTa: non-invasive urothelial carcinoma, pT2: muscle-invasive urothelial carcinoma. 
 
3.4. Invasion depth 
Invasion depth of tumours was measured by the uro-pathologist (C.H.K.). The mean 
invasion depth measured was 1.33mm for TMX-101, 1.42 mm for TMX-202, 1.50 mm for 
vehicle, and 1.39 mm for the NaCl group. The mean invasion depth of tumour positive 
bladders did not show significant differences between individual treatment groups 
(independent samples T test, p=0.486 – 0.912), or between TMX-groups and control-
groups (independent samples T-test p=0.705). 
 
4. Discussion 
The current standard of adjuvant treatment of high-risk UC is intravesical therapy with 
BCG. Despite common local and systemic side effects, BCG is still used widely because 
it is the superior treatment in reduction in risk of recurrence and progression2,3. 
However, there is a need for drugs with less side effects, and alternative drugs in case 
of BCG unavailability22. As potential treatment options for urothelial carcinoma, the 
TLR-7 agonists TMX-101 and TMX-202 are subjects of research. The goal of the TLR-7 
agonists TMX-101 and TMX-202 is a local immune response leading to antitumor 
activity compared to BCG, but circumventing the use of live attenuated mycobacteria, 
and thus preventing side effects. While normally being activated by ssRNA, research 
showed that TLR-7 can be activated equally by artificial ligands such as imiquimod23.  




Imiquimod is already successfully used as topical treatment for benign and malignant 
skin lesions9,10, but has also effect on urothelial carcinoma in vitro and in vivo13,14. 
Hypothesizing that the bladder is accessible for ‘topical’ therapy, TMX-101 is a 
formulation of imiquimod for intravesical use and already tested in vivo for 
pharmacokinetics and pharmacodynamics15 and in clinical trials17-19. TMX-101 is further 
developed under the brand name Vesimune by UroGen Pharma. TMX-202 is 
considered a stronger TLR-7 agonist compared to imiquimod20 and may therefore 
have a stronger antitumor activity. Previously, we compared the pharmacodynamic 
and -kinetic properties of TMX-101 and TMX-20216. We showed a dose-dependent 
systemic uptake after intravesical instillation with a maximum plasma concentration 
of TMX-202 being 25-times lower compared to equimolar dosage of TMX-101. Stronger 
local activity combined with lower systemic uptake, may result in a favourable profile 
of TMX-202 compared to TMX-101.  
 
The aim of this study was to evaluate the antitumor effects of intravesical TM-101 and 
TMX-202 compared to vehicle and saline control in an orthotopic and syngeneic 
bladder cancer rat model. After two instillations of TMX-101 or TMX-202 we observed 
more tumour-free rats compared to the vehicle or saline-group; 35,7 and 42.9% versus 
21.4 and 21.4% respectively (not significant). One of the tumour positive TMX-202 
treated rats, however, showed a superficial pTa tumour in contrast to all other rats 
having pT2-tumours. This means that in the TMX-202 group 50% (7/14) rats were 
without invasive tumours. Still, in this study, the trend towards a higher number of 
tumour-negative rats in the treated groups compared to the control groups did not 
reach statistical significance. Because the observed therapy effect in our experiment 
was below the estimated 50%, the study was underpowered. Setting up this study we 
estimated the therapy result based on in vivo studies of imiquimod on urothelial 
carcinoma12,24 and TMX-202 in a dermatological experiment20.  
 
There are, however, obvious differences between cutaneous application and an 
intravesical instillation with regard to duration of exposure. The TLR-7 agonists may 
need a longer duration of exposure to fully exert their role as immunomodulator. TLR-
7 activation via the MyD88-pathway leads to transcription factors such as NK-κB and 
production of inflammatory cytokines, resulting in the recruitment of activated 





The treatment of malignant skin lesions by imiquimod may take up to several weeks. 
In addition, for intravesical therapy with BCG it is known that the cellular response may 
take up to weeks to develop, but interestingly may persist for over a year after 
induction therapy26. Our experiment had a duration of 12 days with a total of two 
instillations, which may have been too short for optimal antitumor response. Rapid 
tumour development prevented a longer duration of our experiment. 
 
The half-life of cutaneous imiquimod is between 21 and 27 hours, with very limited 
systemic distribution27. It is easily applied, and treatment regimens vary between 3 and 
7 applications a week with treatment duration up to 16 weeks10,27. In contrast, 
intravesical exposure time of study drug is aimed at one hour in the clinical situation. 
Prolonged retention times results in distention of the bladder and patients discomfort 
as well as dilution of the drug with urine. Additionally, intravesical instillation requires 
catheterization which is more burdensome than application on skin. Therefore, when 
compared to topical application, daily intravesical administration for weeks will likely 
not be tolerated by patients. Thus, if a TLR-7 agonist would have to be effective in a 
“standard” intravesical regimen of 6 weekly intravesical instillations followed by a 
maintenance scheme, it is of upmost importance that the receptor activation is as 
potent as possible. Since TMX-202 is considered to be up to 100 times more potent but 
with lower systemic uptake compared to imiquimod20 this is a promising candidate for 
intravesical therapy. 
 
Another limitation of our study is the model we used. The orthotopic rat bladder 
cancer model used in this study is considered a well-established bladder cancer model, 
but there are shortcomings. Tumours develop within 3-5 days, and muscle-invasive 
disease is observed in more than 50% of the rats after 6-7 days28. Besides an advanced 
tumour stage, the pathological grade is high-grade (2004 WHO-classification) or grade 
3 (1973 WHO-classification). Consequently, this model resembles high grade muscle 
invasive disease for which in clinical practice a cystectomy is recommended2,3. Ideally, 
a bladder cancer animal model should have been used with a slow-developing tumour, 
with a long non-muscle invasive phase in which the agents are tested. Although we 
aimed for this early stage of tumour development with two instillations of study drugs 
on day 2 and 5, aggressive tumour development might have overtaken the treatment 
effect, resulting in the relative high percentage of tumour positive rats in the 




treatment group. In addition, pretreatment of the bladder may have caused an 
inflammatory response interfering with the TLR-7 induced response. Preconditioning 
the bladder with HCl is needed, as instilled urothelial cells require a damaged urothelial 
barrier for successful seeding21,28. Although the urothelial barrier will restore rapidly28, 
the inflammatory response is visible up to day 12 on histology. As there is no difference 
in degree of inflammation between treatment and control groups, this is likely a result 
of pretreatment. For future experiments, a control group without seeded tumour cells 
may be included, to isolate the inflammatory effect of TLR-7 activation. 
 
Finally, the presence of a solid and bulky tumour, as seen in our experiment, may 
hamper both optimal TLR-7 activation as well as an efficient cellular response resulting 
in antitumor efficacy. A phase two study showed no ablative effect of TMX-101 after 6 
instillations in patients with a low grade pTa bladder tumor19. In the normal clinical 
situation, first a TURBT will be performed to resect all (or most of the) tumour. 
Additional intravesical therapy aims at a small residual tumour load, superficial 
carcinoma in situ and/or on preventing new tumour development and progression. A 
potential better efficacy in case of a low tumour load was suggested in a phase 2 pilot 
study, with TMX-101 a complete response was obtained in two of ten patients with 
carcinoma in situ after 6 weekly instillations17.  
 
Data on imiquimod and bladder cancer in the literature are limited. Two in vivo studies 
by the group of Scherr et al. showed a substantial decrease on tumour development 
after one24 or two12 intravesical instillations of imiquimod in the orthotopic bladder 
cancer C3H/JeJ mouse model29. In the first study, mice were treated 10 days after 
tumour cell implantation, and sacrificed at day 24. Four of 12 treated mice showed 
tumour, versus all 10 mice in the control group24. The other study describes intravesical 
treatment on day 1 and day 8 after tumour cell implantation, with sacrificing at day 15. 
Here only three of 14 mice showed tumour versus 11 of 13 in the control group12. 
Although the model results in at least 85% invasive tumours, no data on tumour stage 
after treatment was given. These figures indicate a less aggressive model compared 
to the F344-AY27 rat model used in our study. In an in vivo mouse-study, a significant 
reduction of tumour load (measured by bladder weight) is reported after three 
intravesical treatments with imiquimod, in C57BL/6 mice bearing MB49 urothelial 





When bladder weight is used as surrogate marker for treatment effect, we do find a 
significantly lower bladder weight after TMX-202 treatment compared to vehicle, 
although this difference is not significant when compared to other treatment groups.  
 
4.1. Immunotherapy for NMIBC 
Intravesical BCG for the treatment of bladder cancer is the gold standard for more 
than 40 years now and has proven to be the first successful immunotherapy against 
cancer. Apart from the TLR-7 agonists discussed here, recent and ongoing clinical trials 
reporting on immunotherapy for bladder cancer predominantly assess systemic 
checkpoint inhibitors (for example PD-L1, PD-1 and CTL-A4) targeting advanced and 
metastatic disease30,31. However, the PD-1 inhibitor pembrolizumab is evaluated in 
combination with BCG for patients with NMIBC (NCT02808143 and NCT02324582). The 
PD-L1 antibody Atezolizumab is under investigation for the treatment of NMIBC 
(NCT02792192) as well as for patients with CIS (NCT02844816). Other investigational 
drugs aim to boost the immune response initiated by BCG, thereby hoping to improve 
its efficacy. For example intravesical recombinant adenoviral Interferon-α2b32 
(NCT01687244) or the promising IL-15 superagonist complex ALT-803, that is 
administered intravesically in combination with BCG (NCT02138734). Out of the long 
list of promising immunotherapeutic targets30,31, hopefully soon an alternative to BCG 
will emerge, resulting in an improved disease management for patients suffering non-
muscle invasive bladder cancer.       
 
5. Conclusions 
In this in vivo experiment we tested the TLR-7 agonists TMX-101 and TMX-202 in an 
orthotopic bladder cancer rat model. Treatment with two intravesical instillations of 
TMX-101 or TMX-202 resulted in less tumour bearing rats compared to vehicle or saline 
control groups, although not statistically significant. This experiment turned out to be 
underpowered but in this aggressive bladder cancer model, a lower number of tumour 
positive rats after treatment with TLR-7 agonists indicate a promising potential for the 
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Purpose: Imiquimod, a toll like receptor 7 (TLR-7) agonist, is effective as a topical 
treatment for skin malignancies. TMX-101 is a liquid formulation of imiquimod. In this 
study we establish a safety profile of TMX-101 in patients with non-musical invasive 
bladder cancer. 
 
Materials and Methods: We conducted a multicentre phase 1 dose escalation study in 
patients with non-muscle invasive bladder cancer. Patients were included in 1 of 4 dose 
groups (0.05%, 0.1%, 0.2% or 0.4%) and treated with 6 weekly instillations of TMX-101, 
starting 2 weeks after transurethral resection of bladder tumour. Patients were 
evaluated weekly, and pharmacokinetic and pharmacodynamic parameters were 
measured. 
 
Results: A total of 16 patients were included in the study with 4 per dose group. Two 
patients dropped out after instillation 2 in dose groups 1 and 2. Overall, 88 instillations 
were administered without serious adverse events. There were 118 adverse events, of 
which 84 were related to the study drug. All adverse events were mild or moderate 
and number or severity was not correlated with dose group. Of the related adverse 
events 70% were confined to the genitourinary tract and resolved without 
intervention. There was a dose dependent systemic uptake with low plasma levels up 
to dose group 3 (0.2%, 100 mg). Maximum plasma concentration in dose group 4 (0.4%, 
200 mg) was 71.7 ng/ml. This is below plasma concentrations of 123 and 128 ng/ml 
without significant side effects measured in healthy volunteers after subcutaneous 
(30 mg) or oral intake (100 mg) of imiquimod, respectively. 
 
Conclusions: Intravesical treatment with TMX-101 is safe. The side effects are common 
but mild and mostly limited to the genitourinary tract. There is a low systemic uptake. 
  





Bladder cancer causes a considerable burden for patients and seems to be the most 
expensive cancer.1 Therefore, bladder cancer is an important health care problem with 
approximately 2.7 million patients worldwide.2,3 Approximately 75% of bladder cancer 
is non-muscle invasive.4,5 According to EAU (European Association of Urology) 
guidelines, the choice of treatment depends on the risk group to which the patient 
belongs.4,5 All patients should undergo TURBT followed by an immediate intravesical 
instillation of chemotherapy, which has been shown to significantly reduce recurrence 
rates.6 This treatment is sufficient for low risk patients, but intermediate and high risk 
patients should receive additional treatment. The EAU and American Urological 
Association guidelines advise maintenance intravesical chemotherapy for 
intermediate risk patients, whereas patients with high risk NMIBC should receive 
intravesical BCG, which is considered the optimal adjuvant treatment.4,7,8 Despite 
having been the most widely used intravesical treatment for more than 35 years,9 BCG 
is associated with local and systemic side effects in a significant proportion of 
patients.10-12 Moreover, in about a third of patients, bladder cancer recurs,5,13 stressing 
the need for better and safer treatments. 
Toll like receptors are proteins with a critical role in antimicrobial immunity and are 
key components of the innate immune system. Activation of the receptor results in an 
efficient antigen presentation by mature dendritic cells and enhanced production of 
antigen specific T cells.14 Evidence also suggests that this TLR pathway, and especially 
TLR-7, may be crucial in antitumor immunity.15 In the family of imidazoquinolines, the 
synthetic drug imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine) is a 
TLR-7 agonist and acts as an immune modulator via the MyD88 dependent pathway, 
with a potent antiviral and antitumor effect. Imiquimod is the active ingredient of 
Aldara™ cream, which is used for the treatment of genital warts, basal cell carcinoma 
and actinic keratosis,16 as well as carcinoma in situ of the glans penis.17 TMX-101 is an 
optimized formulation of imiquimod, suitable for intravesical instillation.18,19 Previous 
preclinical research showed that imiquimod has an antiproliferative effect against 
urothelial carcinoma in vitro,20 as well as an antitumor effect20 and a good safety profile 
in vivo.19 In this study we established a safety profile of TMX-101 in patients with low 
and intermediate risk NMIBC. Therefore, we conducted a phase 1 dose escalation 






2. Materials and methods 
After approval from the ethical committee, patients were included in this open label, 
multicentre, prospective phase 1 trial from June 2010 until November 2011. In this study 
16 patients were treated at 4 Dutch hospitals. 
 
2.1. Patient Selection 
Patients with a bladder tumour judged to be a Ta–T1 low grade tumour were asked to 
participate before undergoing TURBT. Written informed consent was obtained before 
screening. Patients were eligible if they had pathology confirmed pTa–pT1 low grade 
(WHO 2004) urothelial carcinoma, if they were 18 years old or older, had an Eastern 
Cooperative Oncology Group performance score of 0 to 1, and if they had adequate 
renal, hepatic and haematological function. Women of childbearing potential and 
sexually active men had to agree to use contraception during the study. Exclusion 
criteria were pT1 high grade bladder cancer, carcinoma in situ, high grade cytology, 
muscle invasive urothelial carcinoma, inability to retain an intravesical instillation for 1 
hour, uncontrollable infections, history of upper urinary tract disease, immune 
compromised patients, active malignancies other than urothelial carcinoma and basal 
cell carcinoma, previous or present radiotherapy or brachytherapy, suspicion of 
hypersensitivity to the study drug, pregnant or breastfeeding women, participation in 
other studies with investigational drugs, intravesical chemotherapy within 6 months 
before study entry and intravesical immunotherapy within 24 months before study 
entry. 
 
2.2. Treatment and Study Design 
Treatment consisted of a macroscopically complete TURBT followed by 6 intravesical 
instillations with TMX-101 once a week for 6 weeks. The study drug TMX-101 is a 50 ml 
sterile liquid solution applied intravesically and retained for 1 hour. Included patients 
did not receive a single postoperative instillation with chemotherapy. 
The study was designed as a dose escalation study with 3 to 6 patients per dose group. 
Dose escalation and/or patients per dose group were per protocol defined based on 
dose limiting toxicities and maximum tolerated dose. DLT was defined as any CTCAE 
grade 3 or more toxicity related to the trial medication, and/or any treatment delay of 
21 days or more due to drug related adverse events.  




Maximum tolerated dose was defined as the highest dose level at which less than 33% 
of patients experienced DLT, with a minimum number of 6 patients. The schedule 
consisted of dose groups 1 through 4 with doubling concentrations of TMX-101 of 
0.05%, 0.1%, 0.2% and 0.4%, respectively. 
 
2.3. Patient Evaluation 
The presence, severity and frequency of adverse events were assessed in the weeks 
after treatment, and defined according to CTCAE version 4.2. Patients were monitored 
routinely every week with the assessment of vital signs, blood analysis (haematology, 
chemistry, immunoglobulin) and urinalysis (culture, macroscopic and microscopic). 
 
2.4. Pharmacokinetics and Pharmacodynamics 
Urine samples for pharmacokinetic and pharmacodynamic investigations were 
obtained from all patients pre-dose and 1 hour after instillation. Furthermore, blood 
and urine sampling for pharmacokinetic and pharmacodynamic investigation was 
performed in 1 patient per dose group at points pre-dose, 0.5, 1, 1.5, 3, 4.5 and 6 hours, 
at treatment numbers 1 and 6. For these patients an additional written informed 
consent was required. Blood samples were collected in lithium-heparin tubes, 
transported on ice, centrifuged at 2,500 rpm for 15 minutes at 4C within 30 minutes 
after collection. Aliquoted plasma was stored and shipped at -20C upon analysis. 
Plasma samples were analysed for concentrations of the study drug and 2 of its main 
metabolites by liquid chromatography-mass spectroscopy with a detection range of 
0.025 to 10 ng/ml. Urine samples were analysed for TMX-101 with a detection range of 
5 to 2,500 mg/ml. ELISA kits were used for the determination of plasma concentrations 
of INF-a (PBL, Interferon Source, Piscataway, New Jersey) and urinary concentrations 
of IL-2, IL-8, INF-g (Pierce, Thermo Fisher Scientific Inc, Rockford, Illinois) and IL-18 
(MBL, Woburn, Massachusetts), since these downstream markers may indicate a 
proinflammatory reaction.21 All plasma and urine analyses were performed by a 











At 4 Dutch sites a total of 23 patients were screened. Of these patients 7 were not 
enrolled because of scheduling issues (4), a histologically proven high grade tumour 
after TURBT (2) or an international normalized ratio greater than 1.5 times above the 
upper normal limit (1) (fig. 1). 
Overall 16 patients were enrolled in the study with 4 in each dose group. Patient 
demographics are shown in table 1. In total, 88 intravesical instillations were 
administered. No serious adverse events occurred and no DLT was encountered in this 
trial. 
Two patients (in dose groups 1 and 2) discontinued the treatment after instillation 2 
because of AEs. The complaints resolved without intervention within 2 days. The first 
patient reported a burning sensation of the skin of both legs (CTCAE grade 1) 
unrelated to the study drug. No dermatologic and/or neurological abnormalities could 
be found and the burning sensations resolved without intervention. The other patient 
stopped because of moderate (CTCAE grade 2) burning sensations of the penis and 
rectum, and bladder pain related to TMX-101.  
 
 
Figure 1: Patient inclusion 
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Table 1: Patient characteristics  
 N (%) 
Total number of patients 16 (100) 
Gender  
 Male 11 (69) 
 Female  5 (31) 
Age   
 Mean, years (SD) 58 (12.6) 
 Range, years 39 - 86 
Bladder cancer history  
 Primary 3 (19) 
 Recurrent 13 (81) 
 Mean time from diagnosis, years  7.25 
Bladder cancer stage at inclusion  
 Ta 15 (94) 
 T1 1 (6) 
Bladder cancer grade at inclusion  
 Grade 1 (1973 WHO) 5 (31) 
 Grade 2a (1973 WHO) 11 (69) 
 
3.1. Adverse Events 
All but 1 patient (in dose group 2) reported 1 or more AEs. All of the 118 reported AEs 
were CTCAE grade 1 or 2 and 84 AEs were related to the study drug. Of the treatment 
related AEs 70% was limited to the genitourinary tract. The most common reported 
AEs were urgency (27 AEs in 6 subjects), dysuria (12 AEs in 5 subjects), bladder spasm 
(8 AEs in 3 subjects), fatigue (4 AEs in 3 subjects), bladder pain (2 AEs in 2 subjects) 
and diarrhea (2 AEs in 2 subjects). All related AEs were mild or moderate, and generally 
resolved the same day without treatment. In 1 patient in the lowest dose group there 
was a clinically significant increased C-reactive protein (21 mg/L) which returned to 
normal (less than 10 mg/L) within 7 days. There was no significant difference between 
dose groups with regard to the number of AEs, the intensity of the AEs or the 
relationship with treatment (chi-square p 0.117, table 2). In 4 of the first 12 patients 
urge complaints and bladder spasms during treatment resulted in a retention time 
shorter than 30 minutes, possibly caused by the low pH of the instillation. Therefore, 





the patients in dose group 4. This modification was discussed with and approved by 
the ethical committee. Fewer CTCAE grade 2 events occurred in this dose group but 
the overall tolerability of the instillation did not improve. Mean drug retention time of 
the drug was 44 minutes (SD 17). 
 
Table 2: Number of dug related adverse events per CTCAE grade and dose group.   
(CTCAE : Common Terminology Criteria for Adverse Events) 





1. TMX-101 0.05% 10 12 22 
2. TMX-101 0.01% 10 10 20 
3. TMX-101 0.2% 11 12 23 
4. TMX-101 0.4% 15 4 19 
Overall 46 38 84 
 
3.2. Pharmacokinetics 
Blood for plasma analysis was drawn after instillations 1 and 6 of TMX-101 in 1 patient 
per dose group. Because the patient in the first dose group discontinued after 
instillation 2, another patient was included. Pharmacokinetic analysis showed low 
systemic uptake (less than 8 ng/ml) until dose group 3. For dose group 4 Cmax was 71.7 
ng/ml. This patient showed no systemic side effects. Maximum concentrations were 
reached between 30 and 90 minutes after the start of the instillation (Table 3 and 
Figure 2). 
 
Table 3: Pharmacokinetics of TMX-101.  
 Dose group 1 
0.05% 
Dose group 2 
0.1% 
Dose group 3 
0.2% 
Dose group 4 
0.4% 
Instillation nr: 1* 6 1 6 1 6 1 6 
Dose (mg) 25 25 50 50 100 100 200 200 
Cmax (ng/mL) 3.14 4.33 1.64 7.62 1.74 2.23 59.00 71.70 
Tmax (min) 90 30 90 60 30 30 90 60 
AUC (ng*h/mL) 5.99 9.71 5.16 15.97 5.14 4.54 170.10 157.40 
*data for dose group 1, 1st instillation are combined data from two patients.  
Cmax = maximum plasma concentration, Tmax = time point of maximum plasma 
concentration, AUC = area under curve. 





Figure 2: Pharmacokinetics. Plasma concentration of imiquimod after instillation 1 (A) and 
instillation 6 (B). Error bars represent standard error of mean. 
 
3.3. Pharmacodynamics 
Plasma concentrations of INF-a were determined in 1 patient per dose group. In 2 
patients plasma INF-a was detectable but no difference was found before vs after 
dose. Urine concentrations of IL-2, IL-8, IL-18 and INF-g were determined in urine 
samples of patients before and after all instillations. Analysis of urinary IL-2 and INF-g 
was limited to the first 2 dose groups due to undetectable levels. Urine levels of IL-8, 
IL-2 and INF-g showed no relation to the instillations. Baseline IL-18 levels were below 
the detection limit in almost all patients, increased 1 hour after the instillation and 
returned toward baseline before the next instillation. No correlation was seen 
between IL-18 levels and dose group. 
 
4. Discussion 
TMX-101 is a TLR-7 agonist suitable for intravesical use. It acts as an immune modulator 
in exerting a local immune response suggested to have an antitumor effect on bladder 
cancer.20 In this phase 1 dose escalation study we demonstrated the safety of 6 
consecutive intravesical treatments with TMX-101 after complete TURBT. After 6 
weekly instillations with TMX-101 there were no serious AEs and no DLT was 
encountered. There was a limited dose dependent systemic uptake with low levels up 
to dose group 3. 
 
The 16 included patients reported 84 AEs related to the study drug. The majority of 
these AEs were limited to the genitourinary tract such as urgency and bladder spasms. 





After treatment with the most commonly used immune modulator, BCG, up to 70% to 
90% of patients reported mild complaints being predominantly irritative voiding 
complaints, cystitis and malaise.9-11 Moreover, systemic side effects (fever, nausea, 
vomiting, infections) also occur after BCG treatment in approximately 30% to 40% of 
patients.12 The number of patients in the present trial is not sufficient for statistical 
comparison to AEs after BCG treatment reported in literature. 
 
TMX-101 is a solution of imiquimod optimized for intravesical use.18 As the active 
ingredient of Aldara cream, imiquimod has proven its efficacy in the treatment of 
genital warts, basal cell carcinoma and actinic keratosis,16,22 and is under investigation 
for the treatment of other (pre)malignant lesions like vulvar intraepithelial neoplasia23 
and melanoma.24,25 Imiquimod is a member of the imidazoquinoline family and acts as 
an agonist for TLR-7. Activation of this receptor results in the maturation of dendritic 
cells, cytokine induction, enhanced antigen presentation and activation of the 
adaptive immune system. These processes account for the antiviral and antitumor 
effects. Furthermore, a direct proapoptotic effect on tumour cells is observed.26,27  
 
It is hypothesized that analogous to the topical administration of Aldara cream for skin 
malignancies, bladder instillation with imiquimod might act as a local treatment for 
bladder cancer with limited systemic uptake. In vitro20 and in vivo18,19 studies have 
shown the efficacy and safety of imiquimod as treatment for bladder cancer. 
In this study we found limited systemic uptake (Cmax less than 8 ng/ml) after 
intravesical administration up to dose group 3 (0.2%). In 1 patient treated with the 
highest dose (200 mg, 0.4%) the systemic uptake was 71.7 ng/ml. This value is still 
below plasma values observed after oral intake (100 mg) or subcutaneous 
administration (30 mg) of imiquimod that were not associated with toxicities (123 and 
128 ng/ml, respectively).28,29 A limitation of our study is the availability of 
pharmacokinetic data for only 1 patient per dose group. Because of ethical 
considerations and patient burden, blood sampling for pharmacokinetics until 6 hours 
after the instillation was only allowed in 1 patient per group. 
Two patients dropped out of the study after instillation 2. Both patients reported mild 
to moderate complaints. One patient reported CTCAE grade 2 bladder pain, burning 
sensation of the penis and an irritated top of the penis, which were related to the 
administration of the drug.  




The AEs of both patients resolved without intervention. These patients were replaced 
to maintain 3 evaluable patients per dose group. Compared to the aim of 1-hour 
retention time, the mean drug retention time in this study was 44 minutes (SD 17). 
Patients who voided earlier than 1 hour reported urgency and a burning sensation in 
the bladder. We hypothesized that the relatively low pH of the instillation (3.6) 
accounted for this reaction. Therefore, the 4 patients in dose group 4 received the 
formulation of TMX-101 with a pH of 4.4 in an attempt to optimize the tolerability. 
However, it seemed that there was no difference in tolerability between the first 3 
doses and the highest dose group. Another explanation for the urgency is the 
proinflammatory activity of imiquimod. In the initiated marker lesion part of this study, 
patients will receive instillations (TMX-101, 0.2% and 0.4%) with the higher pH. It will be 
clarified if the cause of the reduced instillation time is the pH and/or the imiquimod. 
 
In this study we confirmed the safety of 6 consecutive intravesical instillations of the 
immune modulator TMX-101. We are currently conducting a marker lesion trial to 
evaluate the efficacy of TMX-101. Furthermore, there is ongoing preclinical work on a 
second generation compound, TMX-202. This is a highly specific and potent TLR-7 
agonist but with a higher molecular mass and, therefore, possible less systemic 
uptake.30 Based on the results, we consider TMX-101 a promising candidate for the 
intravesical treatment of patients with NMIBC, and further research will have to 
confirm the potential of this drug. 
 
5. Conclusions 
In the search for new adjuvant treatments for NMIBC, intravesical TLR-7 agonists may 
have a future role by acting as immune modulators. In this study we confirmed the 
safety of 6 intravesical instillations of TMX-101, a TLR-7 agonist. In total, 88 instillations 
were administered in 16 patients. There was limited dose dependent systemic uptake. 
The reported side effects were mild or moderate, mostly local and resolved without 
intervention. No dose dependent increase in frequency or severity of the adverse 
events was observed. A marker lesion study is ongoing to investigate the efficacy of 
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Objective: To evaluate the antitumor effect of cyclodextrin curcumin complex (CDC) 
on human and rat urothelial carcinoma cells in vitro and to evaluate the effect of 
intravesical instillations of CDC, BCG and the combination in vivo in the AY-F344 
orthotopic bladder cancer rat model.  
Curcumin has anticarcinogenic activity on urothelial carcinoma and is therefore under 
investigation for the treatment of non-muscle invasive bladder cancer. Curcumin and 
BCG share immunomodulating pathways against urothelial carcinoma.  
 
Methods: Curcumin was complexed with cyclodextrin to improve solubility. Four 
human urothelial carcinoma cell lines and the AY-27 rat cell line were exposed to 
various concentrations of CDC in vitro. For the in vivo experiment, the AY-27 orthotopic 
bladder cancer F344 rat model was used. Rats were treated with consecutive 
intravesical instillations of CDC, BCG, the combination of CDC+BCG or NaCl as control. 
 
Results: CDC showed a dose dependent antiproliferative effect on all human urothelial 
carcinoma cell lines tested and the rat AY-27 urothelial carcinoma cell line. Moreover, 
intravesical treatment with CDC and CDC+BCG results in a lower percentage of 
tumours (60% and 68%, respectively) compared to BCG (75%) or control (85%). This 
difference with placebo was not statistically significant (p=0.078 and 0.199, 
respectively). However, tumours present in the placebo and BCG-treated rats were 
generally of higher stage. 
 
Conclusions: Cyclodextrin-curcumin complex showed an antiproliferative effect on 
human and rat urothelial carcinoma cell lines in vitro. In the aggressive orthotopic 
bladder cancer rat model we observed a promising effect of CDC treatment and CDC 
in combination with BCG.  





New treatment options for patients with non-muscle invasive bladder cancer (NMIBC) 
are urgently needed. Despite transurethral resection and adjuvant treatment with 
intravesical instillations, these bladder tumours recur in around one third to two-thirds 
of patients, depending on risk category1,2. Based on tumour characteristics and other 
parameters, the NMIBC-patient is classified in a risk-category and treated adjuvant: in 
general, intermediate-risk patients receive intravesical chemotherapy whereas 
intermediate- and high-risk patients are treated with intravesical Bacillus Calmette 
Guérin (BCG)2. Even after BCG-treatment for 1-3 years, the 5-yr risk of recurrence is 
41.3%1. 
Besides suboptimal oncological results, BCG has considerable side effects ranging 
from mild urogenital complaints to severe systemic side effects. Additionally, due to 
recent BCG shortage, future alternatives for adjuvant treatment are more than 
welcome. 
Curcumin is a component of dried turmeric powder; a food spice derived from the 
plant Curcuma Longa. Curcumin is a nontoxic agent, with anti-inflammatory, 
antioxidant and anticarcinogenic activity3,4, including apoptotic effects on urothelial 
carcinoma (UC) in vitro5,6 and in vivo7-10. The molecular mechanisms underlying the 
antitumor effect have not been fully unravelled. Treatment with curcumin leads to 
downregulation of cell-signalling pathways responsible for proliferation, invasion and 
angiogenesis7,11-13 by suppressing activating transcription factors like NF-κB7,14.  
Curcumin also enhances pathways mediated by tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL), an apoptosis-inducing cytokine that targets human 
cancer cells specifically15. Interestingly, induction and expression of TRIAL by 
polymorphonuclear neutrophils are a key step in the therapeutic effect of BCG 
treatment for NMIBC13: the relative specificity of TRAIL to tumour cells may explain 
the selectivity of the BCG-induced immune response against bladder cancer13. 
Curcumin may potentiate the efficacy of BCG, since it upregulates the expression of 
DR-5, one of the main receptors for TRAIL7,15. Sharing pathways responsible for 
tumour selective apoptosis, curcumin and BCG may have a synergistic antiproliferative 
effect on UC7.   
Because the aqueous solubility of curcumin is low, the bioavailability after systemic or 





Complexing the curcumin to cyclodextrin improves the aqueous solubility17, thereby 
increasing its cellular uptake and efficacy in vitro and in vivo18,19. Using a pH shift 
method, we prepared a concentrated aqueous solution of cyclodextrin curcumin 
complex (CDC) which is stable even in the presence of only two molar excess of 
cyclodextrin (L. Vaahtera and J. Parkkinen et al, unpublished results), suggestive of 
improved bioavailability.  
In view of the antitumor effects of curcumin on UC, the accessibility of the bladder for 
local therapy, and the potential synergistic effect of CDC and BCG, we hypothesized 
that CDC may be a treatment modality for NMIBC. In this preclinical study, we tested 
the antiproliferative effect of CDC on various bladder cancer cell lines in vitro and the 
efficacy of CDC, BCG and a combination of CDC+BCG as intravesical treatment for 
bladder cancer in a syngeneic orthotopic bladder cancer model in rats.  
 
2. Materials and methods 
2.1. Study Drugs 
Cyclodextrin-curcumin (CDC) 12 mg/ml was prepared by a pH shift method: In a 0.18 
mol/L sodium hydroxide solution, 112 g/L hydroxypropyl-γ-cyclodextrin (Wacker 
Chemie, Munich Germany) and 15 g/L curcumin (Sabinsa Corporation, East Windsor, 
NJ, USA) was dissolved and the pH was adjusted to 6.0 using hydrochloric acid and 
citric acid. This method yields a concentrated aqueous solution of curcumin (32 
mmol/l) in the presence of 2-fold molar excess of hydroxypropyl--cyclodextrin. The 
stock solution was sterile filtered and diluted to the proper concentrations with 
serum-free RPMI-1640 medium (Invitrogen, Carlsbad, California, USA) for in vitro 
experiments or with 0.9%NaCl for in vivo experiments. This CDC solution meets the 
pharmaceutical requirements for intravascular administration. 
For the in vivo experiments, BCG-Medac (Medac GmbH, Hamburg, Germany), RIVM 
strain 1173-P2, 2x108 – 3x109 colony forming units was used. It was resuspended in 











2.2. In vitro experiment  
2.2.1. Cell lines and conditions 
Human UC cell lines RT4, RT112, 253J and T24 represent well differentiated, moderately 
differentiated (2x) and poorly differentiated phenotypes of UC respectively.  
The AY-27 rat UC cell line used, was established from a primary bladder tumour in 
FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide) fed Fischer F344 rats.   
Cells were cultured as a monolayer in RPMI-1640 medium with L-glutamine 
(Invitrogen, Carlsbad, California, USA), supplemented with 10% foetal calf serum 
(Sigma-Aldrich, St. Louis, Missouri, USA), 100 U/mL penicillin G and 100 μg/mL 
streptomycin (Invitrogen, Carlsbad, California, USA) in a humidified 95% air/5% CO2 
atmosphere at 37°C. The medium was replaced twice a week. When confluent, cells 
were split using standard trypsinisation procedures.  
 
2.2.2. Cell viability 
 Cells were seeded in 96-well plates at 1*104 cells/well in 100μL culture medium. After 
24 hours, the medium was replaced by 100μL study drug. CDC was dissolved in serum-
free medium at 0.6125 to 640 μmol/L. The AY27 cells were treated for 0.5, 1 or 2 hours 
and the human cell lines for 1 hour. After treatment, the cells were rinsed three times 
using serum-free medium, then 100μL normal medium was added. At one or three 
days, a MTT cell viability assay was performed according to the manufacturers’ 
instruction (Sigma-Aldrich Co, St. Louis, Missouri, USA). The experiments were 
performed in quadruplicate.  
 
2.3. In vivo experiment 
2.3.1. Animals 
Study design and animal procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC), Committee for Animal Experiments (Radboud University 
Nijmegen Medical Centre, The Netherlands) and in compliance with Dutch and 
European regulations. Eighty Fischer F344 rats were purchased (Charles River, 
L’Arbresle Cedex, France) and were acclimatized for one week before the experiment. 
The rats, weighing 170g ± 10g, were housed in cages (Techniplast, Milan, Italy) with 
gold flake bedding (SPPS, Frasne, France) and environmental enrichment, with free 






The sample size of 20 rats per group was calculated with α=5%, power of 80%, tumour 
development in 80% of the rats20 and an estimated therapeutic effect of 50%.  
 
2.3.2. Tumour implantation  
The rats received tumour cells in the bladder at day 0 as described by Xiao et al21. 
Before catheterization, enrofloxacin (Bayer, Leverkusen, Germany) (5-10 mg/kg) was 
injected subcutaneously for antibacterial prophylaxis. Experiments were performed 
under inhalation anaesthesia: Isoflurane 2-5% (induction), followed by Isoflurane 2% 
and oxygen 1 L/min. The urethra was catheterized with a 16-gauge plastic intravenous 
cannula (BD Biosystems, Erembodegem-Aalst, Belgium) and drained. The bladder was 
preconditioned with a 15 sec instillation of 0.4 mL 0.1 M hydrochloride and neutralized 
by adding 0.4 mL 0.1 M potassium hydroxide for 15 sec. The bladder was drained and 
flushed 3 times with 0.8 mL 0.01 M PBS. AY27 cells were harvested, counted and 
resuspended in medium to reach a concentration of 3*106 cells/mL. Within 30 minutes 
after harvesting, 0.5mL of the cell suspension was instilled in the bladder and left 
indwelling for 1 hour. The rats were rotated 90° every 15 minutes to optimize bladder 
exposure. After 1 hour, the catheter was removed.  
 
2.3.3. Study design and treatment 
The rats were treated intravesically three, seven and ten days after tumour cell 
implantation. First, the rats were anaesthetized as described before. The urethra was 
catheterized, and the bladder was emptied by gentle pressure on the abdomen. Group 
1 was treated with 0.5mL 300μmol/L curcumin-cyclodextrin complex dissolved in 0.9% 
NaCl. Group 2 was treated with 0.5mL BCG (BCG-Medac (Medac GmbH, Hamburg, 
Germany), RIVM strain 1173-P2, 2x108 – 3x109 CFU). Group 3 received first an instillation 
with CDC for one hour and, after rinsing three times with NaCl, an instillation for one 
hour with 0,5 mL BCG. Group 4 received 0.5 mL 0.9% NaCl intravesically as placebo. 
After treatment, the bladder was emptied.  
 
2.3.4. Tumour evaluation  
At day 14, the rats were sacrificed using carbon dioxide inhalation. Internal organs 
were inspected for abnormalities. The bladder was removed, weighed, fixed in 
formalin 4%, (Boom B.V., Meppel, The Netherlands), laminated in 1-2mm slices and 
embedded in paraffin.  




Sections of 5μm at two depths per lamella were stained using haematoxylin and eosin. 
A specialized uropathologist (C.H.K.) evaluated tumour stage according to the TNM-
classification and tumour grade according to the 2004 WHO/ISUP classification. The 
degree of inflammation in mucosa and submucosa was quantified as no reaction, mild, 
moderate or severe inflammation. 
 
3. Results 
3.1. In vitro 
One hour of CDC treatment of UC cell lines resulted in a dose dependent 
antiproliferative effect (Figure 1). The 50% inhibitory concentration (IC-50) of CDC in 
μmol/L after one and three days of incubation was 15.9 and 17.6 for RT4, 41.3 and 23.5 
for 253J, 15.1 and 28.9 for AY-27, 19.3 and 34.6 for T24, 15.2 and 37.2 for RT112. 
Treatment with 160μmol/L CDC for 1 hour, resulted in complete cell kill. The 
antiproliferative effect was enhanced when treatment was prolonged: when AY-27 
cells were treated for 30, 60 and 120 minutes, the IC-50 of CDC decreased: 16.5 μmol/L 
after 120 min treatment, 28.9 μmol/L after 60 minutes and 55.1 μmol/L after 30 minutes 






















Figure 1: Relative cell survival at 24 hours (A.) and 72 hours (B.) of four human urothelial 
carcinoma cell lines and one rat urothelial carcinoma cell line (AY27) after 1 hour treatment with 
cyclodextrin-curcumin (CDC). Cell viability relative to untreated cells. Error bars represent 




Figure 2: Relative cell survival of rat urothelial carcinoma cells (AY27) after treatment with 
cyclodextrin-curcumin (CDC) for 30, 60 and 120 minutes. Cell viability relative to untreated cells. 
The MTT cell-survival assay was performed 3 days after treatment. Error bars represent standard 
error of the mean (SEM). 




3.2. In vivo 
3.2.1. Macroscopy 
The rats received three instillations with CDC, BCG, CDC+BCG or NaCl. Two rats died 
during the experiment. One rat (CDC+BCG group) died one day after tumour cell 
instillation and was excluded from the analysis. The other rat (NaCl group) died just 
after the second instillation during anaesthetic emergence. This rat had a pTa tumour 
and was included for the pathologic stage evaluation. At necropsy, no abnormalities 
were found on abdominal organs in both rats and the bladders were intact. 
The other 78 rats recovered well from four times anaesthesia and three instillations. 
There were no signs of impaired wellbeing or infections. Two (tumour positive) rats 
(CDC+BCG and NaCl-group) had haematuria, but showed no other signs of tumour 
related problems. At necropsy, no abdominal abnormalities were found. 
 
3.2.2. Pathology 
The number of tumour-free rats was eight (40%) in the group treated with CDC; five 
(25%) in the group treated with BCG; six (36.6%) in the group treated with CDC+BCG 
and three (15%) for the NaCl-group (Table 1). The number of tumour-free rats was 
higher in the CDC and CDC+BCG group compared to the NaCl-control, but this did not 
reach statistical significance (Fischer’s Exact Test p=0.078 and 0.199 respectively). All 
tumours represented high-grade UC. Tumour stages included pTa, pT1, pT2 and pT3 
and were not related to the treatment group (Kruskal Wallis test, Chi2=3.95, p=0.267). 
Fourteen days after tumour induction, the tumour progressed to a muscle invasive 
bladder tumour in 50.6% of the rats. Half of the pT3 tumours were seen in the NaCl 
group. Three of the four pT3 tumours in the NaCl group showed macroscopically 













Table 1: Pathological stage per treatment group.  
Treatment group Tumour free 
pT0 
N  (%) 
NMIBC 
pTa, pT1 
N  (%) 
MIBC 
pT2, pT3 
N  (%) 
Total 
 
N  (%) 
1. CDC 8 (40.0) 4 (20.0) 8 (40.0) 20 (100) 
2. BCG 5 (25.0) 2 (10.0) 13 (65.0) 20 (100) 
3. CDC+BCG 6 (31.6) 6 (31.6) 7 (36.8) 19 (100) 
4. NaCl (control) 3 (15.0) 5 (25.0) 12 (60.0) 20 (100) 
total 22 (27.8) 17 (21.5) 40 (50.6) 79 (100) 
CDC: Cyclodextrin-curcumin, BCG: Bacillus Calmette Guérin, NMIBC: Non-muscle invasive 
bladder cancer, MIBC: Muscle invasive bladder cancer. 
 
3.2.3. Inflammation 
Nineteen rats (23.8%) showed no signs of inflammation, 46 (57.5%) showed mild and 
15 (18.8%) showed moderate inflammation of the bladder. Severe inflammation was 
absent. Bladder inflammation was characterized by a granulomatous reaction with 
influx of macrophages and polymorphonuclear lymphocytes. There was no difference 
in the nature or degree of inflammation between treatment and/or NaCl group(s).  
 
4. Discussion 
Curcumin, a food spice, is a nontoxic agent with antiproliferative activity against 
urothelial carcinoma (UC) in vitro5,22,23 and in vivo7-10. Because the bioavailability of 
curcumin is hindered by its poor water solubility, cyclodextrin-curcumin (CDC) 
complex was produced to improve its solubility, stability and bioavailability.  
In this study, we show that CDC exerts a dose dependent antiproliferative effect on 
human and rat UC cell lines. Moreover, intravesical treatment of CDC with and without 
BCG in rats bearing bladder cancer resulted in a lower number of tumour-positive rats 
compared to the NaCl-control group although this did not reach statistical 
significance.  
 
4.1. In vitro 
Five UC cell lines were treated with CDC for 1 hour, to mimic the clinical situation of 
intravesical instillation. The IC-50 varied and ranged from 15.1 to 41.3 μmol/L, likely 
reflecting the different phenotypes of the cell lines.  




The IC-50 are within the range of other in vitro studies on curcumin treatment of 
urothelial cells (3.9-20.5 uM 5) but also other malignant cell types (10.5-14.5 uM in 
mammary, prostate and ovarian carcinoma24). Longer exposure to CDC resulted in 
more cell kill of AY-27; when treatment times doubled, the IC-50 values decreased with 
50%. This may have clinical implications because intravesical treatment typically lasts 
one hour, but extended treatment times depend on the patient’s ability to retain the 
instillation longer.  
The effects of CDC on a two-dimensional cell culture cannot directly be compared to a 
three-dimensional model. Differences in architecture and extracellular matrix alter the 
efficacy of CDC5. Therefore, we conducted an in vivo experiment.  
 
4.2. In vivo 
To resemble the clinical situation as much as possible with consecutive intravesical 
instillations, we used the orthotopic bladder cancer model in F344 rats with syngeneic 
AY-27 UC cells. Rats were treated with an intravesical instillation three, seven and ten 
days after tumour cell implantation and sacrificed on day 14. BCG and a combination 
of CDC+BCG were included as treatment modalities since BCG is standard treatment 
for NMIBC2 and curcumin may potentiate the efficacy of BCG7. 
We demonstrate that treatment with CDC and CDC+BCG results in a lower percentage 
of tumours (60% and 68%, respectively) compared to NaCl-control (85%). This 
difference was not statistically significant (p=0.078 and 0.199 respectively), but we 
observed that the majority of high-stage tumours were present in the NaCl and BCG-
treated rats. In this aggressive model, it is encouraging that we observed less and 
lower-staged tumours in the CDC-treated groups. 
  
Curcumin is under investigation as possible therapeutic moiety for a variety of 
malignancies, including urological tumours. Only few in vivo studies report intravesical 
treatment with curcumin or CDC for a urological malignancy 8-10, but not in 
combination with BCG. Leite et al used an orthotopic mouse model with MB49 UC, 
treated twice weekly with an intravesical instillation of curcumin8. They report a 
significant reduction in tumour size for the treated mice, compared to placebo, but no 
effect on number of tumours or invasion depth. Another in vivo study, using the same 
orthotopic bladder cancer mouse model, treated animals with four intravesical 





They report a positive effect on tumour necrosis in the curcumin treatment rats, but 
no effect on tumour size or number. Opposed to these studies, our experiment used 
tumourfree rats as the endpoint. By using the cyclodextrin–curcumin complex, we 
aimed at higher cellular uptake and improved efficacy because of improved 
bioavailability17,19,25 compared unmodified curcumin used in these studies.  
 
Curcumin and BCG share pathways responsible for a tumour-selective antiproliferative 
effect by suppressing transcription factors, like NF-κB, responsible for proliferation, 
invasion and angiogenesis7,11-13 and by inducing apoptosis via TRAIL7,15. In vitro and in 
vivo evidence indicate additive effects of curcumin and BCG treatment for UC7: 
Intratumorally administered BCG combined with oral fed curcumin immediately after 
tumour grafting resulted in a significant reduction in tumour volume compared to BCG 
alone, curcumin alone or placebo. Although this model is a poor reflection of the 
clinical situation, it shows the possible potentiating effect of curcumin7. Comparing 
this study to our results is difficult, since the bioavailability of both curcumin and BCG 
differs greatly after oral and intratumoral administration, compared to intravesical 
instillation respectively. Moreover, in our treatment schedule animals were treated 
after tumour establishment i.e., in a therapy setting, whereas the other study was 
more of a protective setting. Our experiment did not show an additional or synergistic 
effect of the combination CDC+BCG over CDC alone (31.6% tumourfree rats versus 40% 
respectively). The number of tumour positive rats per group was too low to observe 
statistically significant results between these groups. But interestingly, for tumour 
positive rats, the combination treatment resulted in a slightly higher ratio of 
NMIBC/MIBC compared to the CDC treatment: 6/7 versus 4/8. This indicates a positive 
treatment effect compared to BCG alone (2/13) in the spectrum of tumour 
development from NMIBC to MIBC.  
 
Combination treatments of an immunomodulator with a chemotherapeutic (like 
Mitomycin-C, Gemcitabine, Epirubicin etc.) or with another immunomodulator 
(Curcumin, Interferon) have shown favourable results7,26. Advantages of combining 
agents may lie in a potentiating effect on uptake or synergistic stimulation of 
apoptosis factors, as described before. Future research will focus on the combining 
well-known agents with new or established treatments. 




The results of BCG treatment in our experiment are mediocre. Xiao reports a lower 
percentage of tumour-bearing rats (58%) after BCG treatment in the same AY27 model, 
compared to us (75%)27. Two other in vivo experiments show a comparable and more 
modest result of BCG with 64% and 75% tumourpositive mice after intravesical BCG 
treatment28,29. BCG treatment showed a limited antitumor effect compared to clinical 
data. Possibly, the evaluation time was too short as the induction of the effector T-
cells responsible for the anti-tumour effect, requires a number of days. Moreover, the 
magnitude of T-cell response increases synergistically with each treatment, and may 
need weeks to fully exert its effect30. Longer follow up after treatment may be 
preferable, but because of the aggressiveness of the model, we chose to sacrifice the 
animals after two weeks. Xiao et al. used a different study design; they monitored F344 
rats with AY-27 tumours for 90 days, and euthanized animals when clinical signs of 
tumour progression became apparent 27. Survival studies might have shown 
differences between treatment groups, but considering the advanced tumours in 
many animals, this seems unlikely for our experiments.  
 
Our results indicate that the model used may be too aggressive to evaluate 
investigational agents that need a certain amount of time to fully exert their antitumor 
effect. The AY-27 orthotopic bladder cancer rat model used was first described by Xiao 
et al. Muscle-invasive tumours are to be expected, since the urothelium first needs to 
be damaged before tumour cells can attach and grow21. The model appears to be more 
aggressive than originally described. Hendicksen et al assessed the tumour growth 
over time in the AY27 model, and found that after 6 days, already 40% of the rats 
progressed to MIBC (pT2, pT3)20. Considering that both curcumin and BCG work as 
immunomodulators, rapid tumour development may overshadow the antitumor 
effect. Due to limited penetration depth, intracellular concentration of the drug is 
lower at the base of larger tumours, contributing to possible lower treatment effects. 
In future in vivo studies, ideally the tumour load before start of the treatment should 











Being a nontoxic agent, curcumin possesses a variety of properties making it a 
potential cancer treatment or enhancer of existing treatments. The cyclodextrin-
complexed formulated curcumin with improved bioavailability showed a dose 
dependent antiproliferative effect on the rat AY-27 and various human UC cell lines in 
vitro. Intravesical instillation of CDC for the treatment of bladder cancer with and 
without BCG demonstrated a promising anti-tumour response. Extrapolating to the 
clinical situation, (adjuvant) treatment with CDC deserves a successive study.  
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General discussion and future perspectives 
 
  









The aim of this thesis is to present and discuss novel intravesical immunomodulators 
that contribute to an improved treatment of patients with non-muscle invasive 
bladder cancer (NMIBC).  
 
Because adjuvant intravesical therapy can significantly reduce the chance of 
recurrence and/or progression it plays a role in the disease management of NMIBC. 
While we will focus mainly on intravesical therapy as adjuvant treatment, it is 
important to realize that other factors also contribute to a better disease 
management for NMIBC such as awareness of the disease, risk management, smoking 
cessation, detection and diagnosis, operating techniques and follow-up strategies. 
 
Already for more than 40 years, intravesical instillations of Bacillus Calmette-Guérin 
(BCG) remain the gold standard for the adjuvant treatment of (high risk) NMIBC. It has 
proven superior efficacy compared to intravesical chemotherapy1.  
 
1. Why should we find an alternative to BCG? 
1.1. Efficacy 
First, one can aim for a more efficacious treatment. The initial complete response rates 
for BCG therapy are high and range from 55-66% for high grade papillary tumours to 
70-75% for carcinoma in situ (CIS)2,3. Still up to 78% of NMIBC patients will eventually 
encounter a recurrence, and up to 45% will progress to muscle invasive disease in 5 
years4. Differences in recurrence and progression rates between two large databases 
illustrate the importance of BCG-therapy. For example, in the 2006 article by 
Sylvester4, a patient with a pT1G3 tumour showed a chance of progression of up to 
48% after 5 years. In the pre-BCG era, patients in this database were mainly treated 
with chemotherapy. By comparison, following current guidelines, the chance of 
progression of pT1G3 patients treated with maintenance BCG is around 20% at five 
years as demonstrated by a recent EORTC trial5. There is, however, room for 
improvement since these numbers are still unsatisfactorily high. 
The group of patients failing BCG therapy is very heterogeneous: 1. BCG-refractory 
patients were treated adequately with BCG, but show persistent high grade disease 
at 6 months; 2. BCG-relapsing patients are disease free for more than 6 months, but 
suffer recurrence despite adequate treatment of BCG and 3. BCG-intolerant patients 
cannot complete a course of BCG due to side effects.  




BCG-refractory and -relapsing patients termed ‘BCG-unresponsive’: these patients do 
not benefit from additional treatment with BCG6. To uniform and compare outcomes 
of current and future trials, the FDA further defines the term ‘BCG-unresponsive’ as 
being at least one of the following7: 
- Persistent or recurrence CIS within 12 months after adequate BCG-therapy. 
- Recurrent high-grade pTa or pT1 disease within 6 months of completion of 
adequate BCG-therapy 
- pT1 high-grade disease at the first evaluation following an induction BCG 
course.  
 
Already, a lot of research focuses on development of prognostic biomarkers to predict 
which patients will or will not benefit from BCG therapy which is of clinical importance 
since delaying a radical cystectomy worsens the outcome8,9. Because of the 
heterogenicity of the patients failing BCG-therapy, it is unlikely that a single new 
treatment modality will replace BCG. Rather patient related characteristics will 
determine the future treatment of choice, leading a personalized approach.  
An alternative intravesical treatment modality is chemohyperthermia. By device-
assisted hyperthermia, the efficacy of intravesically instilled Mitomycin-C improved. 
Results of a randomized trial showed a recurrence free survival that was higher 
compared to BCG treatment10. In selected patients, even for the treatment of CIS, it 
appears to be an alternative to cystectomy11.  
To further improve the existing BCG therapy, it has been combined with other drugs.  
Combining BCG with interferon-α was thought to boost the BCG induced innate 
immune response resulting in an improved tumour response. Trials however showed 
no significant effect on the efficacy of the combination compared to BCG alone, while 
side effects (like fever) seemed to be more frequent12-14. The use of both BCG and 
chemotherapy (Mitomycin C) was subject of multiple meta-analysis. Rationale behind 
it are synergistic mechanisms of action. It appears that the combination of MMC and 
BCG reduces recurrences in pTa and pT1 patients, but does not affect the progression 
free survival15-17. In this thesis we discussed the combination of intravesical 
cyclodextrin-complexed curcumin and BCG in a rat model (Chapter 5). We 
demonstrated the feasibility and tolerability of the combination therapy, as well as a 





Although the effect of BCG-therapy in this experiment showed mediocre results 
compared to the clinical situation, the curcumin and curcumin+BCG treated rats 
developed fewer bladder tumours and with a lower stage compared to BCG. The 
mechanism of curcumin as immunomodulator is discussed in §2.4.  
 
1.2. Side effects  
Secondly, one can aim for a treatment with less side effects. The majority of NMIBC 
patients suffer from local side effects like frequency, dysuria or haematuria18. In one-
third of patients, systemic side effects occur like general malaise and fever. Because 
BCG consists of mycobacteria, it may also lead to granulomata or sepsis18,19.  
One of the reasons for the development of the intravesical Toll Like Receptor (TLR)-7 
agonist TMX-101 was to trigger an immune response comparable to BCG but 
circumventing the use of live micro-organisms. In chapter 4, we showed that in the 
course of six weekly instillations of TMX-101 (0.05% to 0.4%), almost all patients 
reported adverse events, of which 70% was confined to the genitourinary tract. All side 
effects were mild or moderate and generally resolved within days. Part of these 
complaints can be contributed to the procedure of catheterization and instillation of 
a drug. Also after instillation of chemotherapy 7-39% of patients report local side 
effects20, but differences in both local and systemic side effects are significantly higher 
in BCG compared to intravesical chemotherapy20,21. Following BCG treatment, the 
majority of patients experience local side effects but 30-40% report more systemic 
complaints like fever, nausea or (severe) infections22. It appears that the reported mild 
and moderate local side effects after intravesical TMX-101 are comparable to BCG. The 
number of patients and/or severe systemic side effects was not sufficient to compare 
this to the figures after BCG treatment.  
Part of the side effects can therefore be contributed to the strong local immune 
response and can probably not be avoided. The presence of side effects does not 
result in a better outcome23, as previously believed. It is likely that intravesical 
immunotherapy will always provoke an immune response that may result in some 
degree of discomfort.  
In the phase-1 clinical trial (chapter 4) we observed an increased systemic 
concentration of the study drug after six weekly instillations of TMX-101, potentially 
contributing to systemic adverse events.  




In an attempt to minimize the systemic release while maintaining induction of an 
immune response, we tested another TLR-7 agonist in vivo (chapter 2): TMX-202 
showed a systemic concentration that was 25 times lower compared to equimolar 
dosage of TMX-101. These results are in accordance with a dermatological study 
showing a reduced systemic response of TMX-202 despite being a stronger TLR-7 
agonist compared to TMX-10124.  
Because the mechanism of action of immunomodulators like BCG and TLR-7 agonists 
is complex, it is difficult to pinpoint the main contributor to the side effects. It is likely 
that the combination of Toll-like receptor activation, cytokine release and the T-cell 




A limited number of pharmaceutical companies manufacture BCG. In 2011 a BCG 
shortage occurred when the factory of a major BCG-producing company in Canada 
was closed after fungal colonization due to flooding of the factory. The other major 
manufacturer could not increase the production sufficiently leading to a worldwide 
BCG shortage. This led to suboptimal bladder cancer treatment due to the division of 
available BCG dosages between multiple patients, changing BCG treatment schemes, 
using intravesical gemcitabine instead of BCG or ultimately offering patients an early 
cystectomy: clearly an undesirable situation.  
The former shows that the production of BCG is vulnerable. Production time of an 
approved clinical batch of BCG is approximately 3 months as it consists of live 
mycobacteria rather than molecules. In addition, instillations with BCG for the 
treatment of NMIBC demands significantly higher concentrations compared to BCG-
vaccines used to prevent tuberculosis. During the last years, the BCG availability 
improved due to an increased production, but it will remain vulnerable since few 
manufacturers only use few strains. By the end of 2019 Dutch hospitals again 
experienced a temporary scarcity of BCG resulting in delay of treatment.  
Needless to say, a suitable BCG alternative is important to prevent suboptimal 








2. Why treat urothelial carcinoma with immunotherapy? 
Urothelial carcinoma is considered an immunogenic tumour in view of the, albeit 
moderate, success of BCG and the realization that it bears the third highest mutation 
rate of human cancers, after melanoma and small cell lung cancer25. Neoantigens 
produced from these somatic mutations may be recognized by the host immune 
system as foreign antigens. Often, tumour cells manage to evade this recognition 
process, resulting in uninhibited tumour growth. The main goal of immunotherapy is 
to direct the host immune system towards recognition of tumour cells with 
subsequent activation of a mainly T-cell mediated antitumour process.  
 
2.1. Tumour biology 
In a process known as immune surveillance immune cells, particularly natural killer 
cells (NK), continuously sample cells and lyse aberrant cells. Despite this continuous 
surveillance, malignant cells still escape (e.g. by loss of recognition receptors for 
immune cells), ultimately leading to the outgrowth of tumours. Despite the presence 
of neoantigens caused by mutations which may serve to elicit immune responses, 
tumours survive. T-cell recognition is guided by peptides from tumour-associated 
antigens and are presented by Antigen Presenting Cells (APC) in the context of Major 
Histocompatibility Complex proteins (MHC) to induce an immunological response. 
This leads to expansion of specific CD8+ cytotoxic T-cells that infiltrate the tumour 
micro-environment. Here, they recognize and lyse the aberrant cells carrying the 
tumour-associated antigens. Moreover, NK cells are stimulated by the lack of 
inhibitory factors on tumour cells, which also leads to tumour cell lysis. Nevertheless, 
Since T-cell responses are dependent on presentation of the tumour-associated 
peptides in the context of MHC, loss of MHC by tumour cells leads to tumour cell 
escape. Because MHC are present on virtually all nucleated cells in the human body, 
unique tumour-associated peptides need to be recognized to establish the desired T-
cell specificity to attack and lyse tumour cells and spare normal cells 26,27. 
The tumour micro environment (TME) plays a pivotal role in both tumour 
development as well as antitumour processes. The tumour micromilieu is known to be 
immunosuppressive, which may lead to anergy of infiltrating immune cells. Tumour 
cells may secrete inhibitory cytokines such as IL10. Furthermore, inhibitory regulatory 
T cells (T-reg), macrophages and myeloid-derived suppressor cells concentrate in 
tumours, and hypoxia also leads to unfavourable conditions.  




Infiltration of the TME by these suppressive immune cells correlate with worse 
prognosis28 and a lower susceptibility to treatment.  
 
2.2. Checkpoint inhibitors 
Activation of the immune response to fight an infection is a two-way sword. Once 
specific T-cells are expanded and the target has been cleared, the T-cell response 
needs to diminish. I.e., after a powerful immune response, immune checkpoints are 
present preventing the immune system from continuous expansion. Moreover, these 
pathways are also crucial for self-tolerance, which prevents the immune system from 
attacking cells indiscriminately. By upregulating these suppressing checkpoints, 
tumour cells circumvent an attack by the immune system. Over the last decade, 
checkpoint inhibitors have shown spectacular results in the treatment of metastatic 
urothelial carcinoma (UC)29-32. 
Programmed Death(PD)-1 is a receptor on CD8+ T-cells, NK-cells, and Dendritic Cells 
(DC) amongst others. When bound to one of the Programmed Death Ligands (PD-L1 
or PD-L2), T-cell function is inhibited. Blocking PD-1 (Nivolumab and Pembrolizumab) 
or PD-L1 (Atezolizumab, Avelumab, and Durvalumab) results in clinical antitumour 
responses in patient with metastasized UC who failed platinum-based chemotherapy. 
Several landmark studies showed an approximated 15-30% response rate, translating 
in an improved median survival in this otherwise therapy-resistant patient group (for 
example KEYNOTE30, IMvigor31 and Checkmate32 clinical trials). 
Another Checkpoint target is the cytotoxic T-lymphocyte-antigen 4 (CTLA-4) receptor. 
Activation of CLTA-4 is involved in regulating T-cell activation in lymph nodes. Blocking 
CTLA-4 with a monoclonal antibody (Ipilimumab), enables (re)activation of 
antitumour T-cell responses.  
However, not all tumour cells express the checkpoints: In trials with Atezolizumab 
(Imvigor210 29) and Nivolumab (Checkmate 275 32), PD-L1 positive patients showed 
longer overall survival. However, the correlation of PD-L1 expression with response is 
inconsistent, and PD-L1 expression is not considered a surrogate marker for predicted 
therapy effect. With more knowledge about checkpoint regulation, the development 
of agents aimed at other immune checkpoint regulators future combination therapies 
may be more potent. It is important to realize that some patients experience severe 
toxicity, culminating in graft-versus-host disease like symptoms as a result of the 





Although checkpoint inhibitors now have their place in treating metastatic UC, there 
is an interesting shift towards treatment of UC in earlier stages of the disease, thus 
including NMIBC33. Because NMIBC is a localized disease, there is an opportunity for 
intravesical administration of checkpoint inhibitors (NCT03167151). The efficacy of 
adjuvant checkpoint inhibitors in patients with NMIBC is now subject of multiple trials. 
Importantly future studies should not only focus on patients who failed BCG-therapy, 
but also on BCG-naïve patients for two reasons. Firstly, prior BCG-therapy may have 
altered the TME and the mutational status of the tumour, possibly resulting in a 
different antitumor response. Secondly because patients who failed BCG may have 
host- or tumour characteristics that negatively influence immunotherapy in general, 
such as upregulation of immunosuppressive cytokines and selection of cells with a low 
mutational load. 
 
2.3. Tumour micro environment  
As described briefly before, the TME can harbour cellular subsets or concentrations of 
stimulatory/inhibitory proteins that have an immunosuppressive effect. Such tumours 
are regarded “cold” tumours: tumour T cell infiltration is lacking, because tumour 
antigens are insufficiently immunogenic, antigen presentation is defective, T cell 
activation is absent and homing into the tumour bed. Numerous immunomodulating 
agents are under investigation to turn “cold” into “hot” tumours. In many trials 
checkpoint inhibitors are delivered in combination with chemotherapy, targeted 
treatments, vaccines or other treatments to enhance the anti-tumour effects. An 
interesting set of experiments following our experiments would be the determination 
of the immune cell composition of the TME of the rat bladders. Differences in influx of 
NK’s, DC’s, cytotoxic T-cells, macrophages etcetera, could reflect differences in 
treatment effects between for example BCG, curcumin, TMX-101 or TMX-202 treated 
rats, compared to placebo.  
 
2.4. Curcumin 
In chapter 5 we describe an experiment using curcumin as immunomodulator. 
Because curcumin is non-toxic and widely available as a nutrient used in food spices, 
it may play a future role in preventing (recurrences of) NMIBC or in treatment of the 
disease.  




The immunomodulating pathways of curcumin overlap partially with those of BCG: it 
mediates tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) amongst 
others34. TRAIL is an apoptosis-inducing cytokine that targets human cancer cells 
specifically, and is a well-known part of the TME. 
Future research will aim to unravel the role of curcumin in modulating the TME. 
Curcumin treatment may be able to change a cold environment into a TME that is more 
susceptible for other (immune)therapies. It inhibits PD-L1 expression in breast cancer 
cells, making them more susceptible to CTLA-4-blockade35. But also in bladder cancer 
cells, curcumin (bisdemethoxycurcumin in this case), increased intratumoral CD8+ T-
cells infiltration, and decreased the number of myeloid-derived suppressor cells. By 
combining treatment with a PL-L1 inhibitor, CD8+ T-cells were protected from 
exhaustion, prolonging the survival of bladder cancer bearing mice36. These preclinical 
experiments show the potential of curcumin to modulate the TME, making it a good 
candidate in multimodality treatment with for example chemotherapy, checkpoint 
inhibitors or radiotherapy. Curcumin is a non-toxic agent, with supposedly few to no 
expected side effects. Therefore it may be worthwhile in future trials to include a 
study arm with the combination of intravesical curcumin and for example a PD-(L)1 
inhibitor. 
 
2.5. Toll Like Receptors 
An important step in the innate immune system is recognition of pathogen-associated 
molecular patterns (PAMP’s) by Toll Like Receptors (TLR’s). There are 10 known 
human TLR’s and these are capable of recognizing for example Gram-negative 
bacteria (TLR-4), peptidoglycans (PG) of Gram‐positive bacteria (TLR-2) or viral RNA 
(TLR-7). The TLR’s are expressed on macrophages, APC’s and dendritic cells (DC) and 
play a pivotal role in the initiation of the innate immune response. In contrast, TLR’s 
are also expressed on tumour cells. TLR activation may therefore lead to both 
tumorigenic as well as antitumour effects. TLR-2, TLR-4 and TLR-7 agonists have 
proven antitumour effects against urothelial carcinoma37.  
As discussed, the complex mechanism of BCG is not yet completely unravelled. Several 
bacterial cell components stimulate both TLR-2 and TLR-4 leading to release of ligands 






Being a TLR-2 and TLR-4 agonist, BCG causes the release of interleukins (IL‐1, IL‐2, IL‐6, 
IL‐8, IL‐10, IL‐12) TNF‐α and IFN leading to an antitumor Th1‐mediated immune 
response38. In addition, the release of TRAIL has a direct antitumor effect against 
bladder cancer39. 
The TLR-7 agonist imiquimod is widely used for the topical treatment of various 
(pre)malignant skin lesions. The proinflammatory responses after TLR-7 activation 
resemble those seen in BCG treatment, and therefore TRL-7 agonists have been 
proposed as treatment for urothelial carcinoma. In chapter 3 the intravesical use of 
two TLR-7 agonists against urothelial carcinoma in a rat model is discussed. Although 
not statistically significant, the number of tumour-bearing rats was lower in the 
treatment groups compared to the control groups. Despite being underpowered it is 
promising to observe a treatment effect in this very aggressive tumour model. TLR-7 
agonists are also applied in creams on skin for There are important differences 
between intravesical instillation compared to skin application, with pharmacokinetic 
and -dynamic consequences. The shorter exposure time after instillation compared to 
skin application and also the burden of subsequent catheterizations for the patient, 
limiting the frequency of treatment.  
We therefore performed a pharmacokinetic and pharmacodynamic experiment in the 
same F344 rat model (chapter 2), demonstrating the safety of TMX-101, a formulation 
of imiquimod suitable for intravesical administration as well as TMX-202, a novel TLR-
7 agonist with future potential. 
Based on existing data on imiquimod, combined with preclinical studies, the Phase-1 
clinical trial with NMIBC patients was designed and performed. As discussed in  
chapter 4, this trial demonstrated a good tolerability in patients with NMIBC. We 
performed an additional Phase-1 trial, with also a marker lesion40. In seven patients 
there was no complete response on the marker lesion after six instillations of TMX-
101. The short follow up, the low number of instillations and/or the low-grade nature 
of the urothelial carcinoma may have contributed to the non-ablative effect of TMX-
101. A Phase-2 trial on 12 patients with carcinoma in situ demonstrated a complete 
response of two patients after six instillations TMX-101. The suggestion is that high-
grade UC like CIS is more susceptible to a TLR-7 agonist than low grade UC. Also, the 
number of treatments and the total duration are a matter of discussion. The treatment 
regime is often similar to the (historical) BCG-scheme. In contrast, topical imiquimod 
for skin cancer is applied three to seven times a week for 16 weeks.  




Future clinical studies on intravesical TLR-7 agonists may have to focus on high grade 
NMIBC and require a more intense treatment schedule. Moreover, the effect of 
adjuvant immunotherapy may be stronger in flat lesions (e.g. CIS) or in prevention of 
recurrence, rather than ablative (papillary tumours).  
 
2.6. Immunogram 
As mentioned before, the effectiveness of immune therapy as antitumour treatment, 
largely depends on tumour characteristics, including the TME. Contributing factors are 
for example previous immunotherapy, PD(L)-1 expression, FGFR-3 mutation 
(prevalent in NMIBC), molecular subtypes etc. In addition, biomarkers that predict or 
demonstrate a “hot” or “cold” immune environment are envisioned to play a role in 
the future to guide treatment decisions. T-cell activity is the ultimate effector 
mechanism and recent work suggests that seven immunogenic parameters are 
important, which creates the possibility to design an immunogram: tumour 
foreignness (mutational load), host immune status, immune cell infiltration (T-cells as 
well as inhibitory immune cells) , absence of checkpoints (CTLA-4, PD-1), absence of 
soluble inhibitors (cytokines and growth factors), absence of inhibitory tumour 
metabolism (lactate dehydrogenase, indolamine 2,3-dioxygenase 1), and tumour 
sensitivity to immune effector mechanisms (antigen presentation)41. When in the 
future these parameters can be uniformly quantified, a decision-making tool can be 
added to the existing nomograms. 
 
3. Future perspectives 
In addition to the treatments discussed in this chapter, what else can we expect in the 
near future concerning immunotherapy on NMIBC? As discussed before, the 
checkpoint inhibitors will be administered in earlier stages of UC, including NMIBC.  
Numerous Phase-2 and -3 trials focus on BCG unresponsive NMIBC patients, using 
checkpoint inhibitors as monotherapy, for example Pembrolizumab (NCT02625961), 
Atezolizumab (NCT02844816), Durvalumab (NCT02901548), or in combination: 
intravesical Pembrolizumab+BCG (NCT02808143) or Durvalumab+BCG or radiotherapy 
(NCT03317158).  
The remarkable effects of checkpoint inhibitors on urothelial carcinoma has led to 
exciting clinical trials on NMIBC. In the future, selected patients will benefit from first-





Apart from the checkpoint inhibitors, there are other promising developments in 
immunotherapy for NMIBC.  
 
3.1. ALT 803 
Interleukin-15 plays a role in the activation of CD8+ T cells and NK-cells. Alt-803 is a 
protein complex consisting of an IL-15 mutant and a soluble L-15 receptor α/IgG1 Fc 
fusion protein. This complex (ALT-803) shows a biological activity that is up to 25 times 
higher than that of native IL-15. Furthermore, this complex overcomes the short half-
life, high concentrations and subsequent toxicity that limited the clinical use of IL-15 
thus far42. In UC, a reduction of tumour burden was demonstrated when ALT-803 was 
combined with BCG. Currently, a clinical Phase-2 trial in BCG-unresponsive patients 
explores the combination of ALT-803 with BCG (NCT03022825). 
 
3.2. IDO1 
The IDO1 enzyme is activated in NMIBC and plays an important role in tumour immune 
evasion. Small molecules that inhibit IDO1 (Linrodostat, Indoximod, Navoximod, 
Epacadostat) are well studied in various cancers. Because the IDO1 and PD-1/PDL-1 axis 
interrelate, evidence suggests that combining inhibition of both axis leads to a more 
effective activation of the T-cell mediated antitumor response43,44. In the Checkmate 
9UT trial, BCG unresponsive NMIBC patients are treated with nivolumab (PD-1 
inhibitor) or nivolumab plus an IDO-inhibitor, with or without intravesical BCG-
treatment (NCT03519256).  
 
3.3. Gene therapy 
A recombinant adenovirus is used that transfers gene information programmed to 
express human IFNα-2b. By combining it with Syn3 into the formulation rAd-
INFα/Syn3, a Phase-II trial demonstrated tolerability of the intravesical treatment, as 
well as preliminary efficacy for BCG unresponsive NMIBC patients45. CG007 is an 
oncolytic adenovirus that selectively replicates in tumours and causes cell lysis. It was 
tested intravesically in a phase-2 trial in patients with BCG-unresponsive NMIBC 
showing a complete response rate of 47% after 6 months46. The promising aspect of 
these viruses is their tumour selectivity. 
 
 




3.4. Tailor-made treatment plan 
There is a proportion of bladder cancer patients that do not respond to 
immunomodulating treatment. For the various treatments mentioned before (e.g. 
BCG, TMX-101, PD(L)-1 inhibitors, curcumin), the biological basis for this resistance may 
be different.  
The most important step in improving future (immune) therapies for NMIBC will be 
predicting the treatment efficacy resulting in a tailor-made (personalized) treatment 
plan. By using tumour markers, urinary markers, clinical data on previous treatments 
and other patient characteristics, a better (combination of) drugs can be chosen. An 
understanding of the TME is essential to study new drugs and predict treatment 
success. The individualized treatment plan may comprise a combination of 
immunotherapies or adjuvant immunotherapy combined with conventional 
treatment modalities such as surgery (TURBT or cystectomy), chemotherapy 
(intravesical or systemic) or radiotherapy.  
The intravesical route to administer the therapy will remain an opportunity to elicit a 
strong local immune response, minimizing systemic side effects.  
 
4. Conclusions 
Working on novel immunomodulators to treat urothelial carcinoma raises more 
questions than answers. There is a complex overlap between tumour biology, 
immunogenicity and immunomodulators resulting in small scientific steps. The 
breakthrough of checkpoint inhibitors in the treatment of metastatic UC increased the 
attention towards immunomodulators. It is important to use this attention as 
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Bladder cancer is a disease that should not be underestimated. It is the most common 
malignancy of the urinary tract and because of the high chances of recurrence, it 
carries a significant burden for the patient. When a bladder tumour is diagnosed with 
cystoscopy, the first step is a transurethral resection of the tumour. Most bladder 
tumours are urothelial carcinoma and around 75% is non-muscle invasive (NMIBC): this 
is the subject of this thesis. Combining the pathology report with tumour 
characteristics will result in a risk profile on which further disease management 
depends: Low-risk patients require follow up for 5 years. For intermediate-risk 
patients, adjuvant intravesical chemotherapy or intravesical bacillus Calmete-Guérin 
(BCG) is advised. For high-risk patients, intravesical BCG maintenance therapy for 1-3 
years is recommended by the guidelines (chapter 1) 
Already being around for more than 40 years, intravesical BCG-therapy remains the 
gold standard for adjuvant treatment of high-risk bladder cancer. It is the first 
successful immunotherapy for a human cancer. The live attenuated strain of 
mycobacterium bovis results in a localized immune response that has an antitumour 
effect on urothelial carcinoma, also reducing the chance of both recurrence and 
progression. 
 
Despite the adjuvant treatments, the chances of bladder cancer recurrence or 
progression to muscle-invasive disease are high. Depending on the risk category 31% - 
78% of the bladder cancers have recurred in 5 years, even after adjuvant treatment. In 
addition to the modest efficacy of adjuvant intravesical therapies, a lot of patients 
experience side effects ranging from local genitourinary complaints to severe 
infections. Thus, there is a need to improve the current adjuvant therapies for NMIBC. 
Imiquimod is a Toll like receptor(TLR)-7 agonist that is used for the topical treatment 
of (pre)malignant skin lesions. In analogy to this mechanism, imiquimod also showed 
efficacy against urothelial carcinoma. TMX-101 is a formulation of imiquimod suitable 
for intravesical instillation. TLR agonists like imiquimod (TLR-7) and BCG (a TLR-2 and 
TLR-4 agonist) share immunomodulatory pathways. It is therefore hypothesized that 







TMX-202 consist of TLR-7 ligand conjugated to phospholipids, and appears to be a 
highly selective TLR-7 agonist. In chapter 2 we compare the pharmacokinetic and 
pharmacodynamic properties of both TMX-101 and TMX-202 in a rat model. Blood 
sampling of the rats was performed on various time points after intravenous or 
intravesical administration. The experiment showed no signs of significant toxicity. 
After intravesical administration, there was a limited dose dependent systemic uptake 
for TMX-101. The measured systemic concentrations of TMX-202 were 25 times lower 
compared to TMX-101. This difference is explained by the conjugation of TMX-202 
resulting in a higher molecule mass and increased lipophilicity. After intravesical 
administration, no difference was seen in cytokine response between both drugs. The 
cytokines IL-6 and TNFα did show a peak after intravenous administration, indicating 
that both drugs function as a TLR-7 agonist. With the safety and feasibility of TMX-101 
and TMX-202 confirmed, we performed an in vivo experiment, on the efficacy of both 
drugs in a bladder cancer rat model discussed in chapter 3.  
 
Intravesical instillation of isogenic urothelial carcinoma cells started bladder cancer 
development in the rats. Intravesical instillations of TMX-101, TMX-202, vehicle or NaCl 
were given on day 2 and 5 and no signs of toxicity were seen. On the 12th day the rats 
were euthanized and the bladders were evaluated histopathologically. The number of 
tumour-positive rats was higher in the vehicle and NaCl control groups compared to 
the TMX-101 and TMX-202 treated groups, but this did not reach statistical significance. 
In this aggressive tumour model, only two intravesical instillations may have been 
insufficient to fully exert the antitumour effect.  
 
In chapter 4 we discuss a phase-1 clinical trial of intravesical TMX-101 in bladder cancer 
patients. A series of six weekly instillations were administered two weeks after 
transurethral resection of a bladder tumour. A total of 16 patients divided over 4 dose 
groups were included. This study confirms the safety of TMX-101 as intravesical 
treatment as there were no serious adverse events. The majority of the patients 
reported mild to moderate side effects confined to the genitourinary tract. The local 
side effects are comparable to BCG-therapy, but the systemic and severe side effects 
could not be compared to BCG-therapy since these were absent in this trial. 
Pharmacokinetic data showed a low dose-dependent systemic uptake after 





Another type of immunomodulator was tested in vivo. In chapter 5 we describe an in 
vivo efficacy experiment of intravesical curcumin in combination with BCG in the same 
orthotopic bladder cancer rat model discussed in Chapter 3. Curcumin is a yellow food 
spice that has multiple immunomodulatory actions, as well as an antitumour effect on 
urothelial carcinoma. By complexing the curcumin with cyclodextrin, the solubility 
improved, making it a better candidate for intravesical experiments. Curcumin-
cyclodextrin-complex (CDC) was tested in vitro on various human urothelial carcinoma 
cell lines as well as the rat bladder cancer cell line, showing a dose dependent 
antiproliferative effect. For the in vivo experiment, urothelial carcinoma cells were 
instilled in the bladder, starting tumour development. The rats were treated with 
intravesical instillations of CDC, BCG, a combination of CDC and BCG or NaCl as placebo 
on day 3, 7 and 10. On day 14 the rats were sacrificed for histopathologic evaluation of 
the bladder. Although not statistically significant, there was a lower percentage of 
tumour positive rats in the CDC and CDC+BCG group compared to placebo. 
Interestingly, BCG (the clinical standard) showed mediocre results, indicating an 
aggressive tumour model. Even in an environment of rapid progressing aggressive 
tumours, curcumin treatment showed a promising effect.  
 
In chapter 6 we describe the overlapping immunomodulatory pathways of BCG, TLR-
7 agonists and curcumin in the light of recent developments on checkpoint inhibitors. 
The remarkable progress demonstrated by checkpoint inhibitors for the treatment of 
metastasized urothelial carcinoma will advance into the field of NMIBC. The most 
important aspect of future immunotherapy for NMIBC will be to predict treatment 
efficacy upfront, resulting in an individualized treatment plan. This plan will most likely 
consist of a combination of immunomodulators aiming for a lower risk of recurrence 
and progression with fewer side effects compared to current standards. 
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Blaaskanker is een belangrijk gezondheidsprobleem. Het is de meest voorkomende 
kwaadaardigheid van de urinewegen. Omdat blaaskanker de neiging heeft te 
recidiveren is de impact voor zowel patiënt als de gezondheidszorg groot. De 
behandeling van blaaskanker start met een transurethrale resectie van de blaastumor 
op de operatiekamer. Vervolgens wordt een risicoprofiel opgesteld door de 
pathologie-uitslag te combineren met andere tumor-karakteristieken. Bij verreweg de 
meeste blaastumoren is sprake van het urotheelcelcarcinoom en driekwart van alle 
blaastumoren zijn niet-spierinvasief: het onderwerp van dit proefschrift.  
Het verdere behandelplan van blaaskanker hangt af van het risicoprofiel. Laagrisico 
blaaskanker moet vervolgd worden met cystoscopieën gedurende 5 jaar. Voor de 
intermediaire risicogroep worden aanvullende blaasinstillaties met chemotherapie of 
bacillus Calmete-Guérin (BCG) aanbevolen. Internationale richtlijnen adviseren hoog-
risico patiënten te behandelen met BCG-blaasinstillaties in een onderhoudsschema 
voor één tot drie jaar (hoofdstuk 1). 
 
BCG-blaasinstillaties bestaan uit de levend verzwakte vorm van mycobacterium bovis. 
BCG was de eerste succesvolle immunotherapie tegen kanker en bestaat inmiddels al 
meer dan 40 jaar. De werkzaamheid tegen blaaskanker is gebaseerd op een 
ingewikkeld gelokaliseerd immuunproces dat resulteert in een antitumor effect. 
Hierdoor verlaagt BCG behandeling de kans op een recidief en verlaagt het de kans tot 
progressie naar spierinvasieve ziekte. Ondanks de blaasinstillaties is de kans op 
recidiverende blaastumoren nog steeds te hoog. Na 5 jaar lijkt de ziekte bij 31 tot 78% 
minstens eenmaal te zijn teruggekomen. De kans hierop hangt af van het eerder 
genoemde risicoprofiel. De huidige blaasinstillaties zijn niet alleen suboptimaal qua 
effectiviteit, ze geven ook nog eens bijwerkingen zoals urogenitale klachten, infecties 
of sepsis. Er is dus dringend behoefte aan betere aanvullende behandelingen voor het 
niet-spierinvasief blaascarcinoom. 
 
Imiquimod is een Toll-like receptor (TLR)-7 agonist en wordt als crème gebruikt voor 
de lokale behandeling van huidtumoren. Analoog hieraan toont imiquimod ook 
effectiviteit tegen het urotheelcelcarcinoom. TMX-101 is een farmacologische 





(TLR-7 agonist) en BCG (TLR-2 en -4 agonist) hebben overlappende immunologische 
werkingsmechanismen. De hypothese is dat TLR-7 agonisten als blaasinstillatie 
gegeven kunnen worden voor behandeling van blaaskanker en waarbij het gebruik 
van levende mycobacteriën omzeild wordt.  
 
Een andere, selectievere, TLR-7 agonist is TMX-202. Het is een met fosfolipiden, 
geconjugeerde TLR-7 agonist. In hoofdstuk 2 beschrijven we de farmacokinetiek en 
farmacodynamiek van zowel TMX-101 als TMX-202 in een rattenmodel. Na een 
blaasinstillatie of na intraveneuze toediening werd op vaste tijdstippen een 
bloedmonster genomen voor analyse. Er waren geen aanwijzingen voor toxiciteit bij 
dit experiment. Er werd een lage dosis-afhankelijke systemische concentratie TMX-101 
gemeten na de blaasinstillatie. De systemische concentratie TMX-202 was 25 keer 
lager dan die van TMX-101, op basis van de hogere molecuulmassa en een lipofiel 
karakter door de conjugatie. Na de blaasinstillatie werden geen verhoogde 
systemische cytokines gemeten. Na intraveneuze toediening wel wat een indicatie is 
voor de TLR-7 agonerende werking van TMX-101 en TMX-202. Met de toepasbaarheid 
en een indicatie voor de veiligheid van deze middelen, hebben we een experiment 
verricht naar de effectiviteit hiervan in de behandeling van blaaskanker.  
 
hoofdstuk 3 beschrijft het in vivo experiment van TMX-101 en TMX-202 in het 
orthotope blaaskanker rattenmodel. Een blaasinstillatie met genetisch identieke 
blaaskankercellen start de tumorontwikkeling. Op de 2e en 5e dag wordt een 
blaasinstillatie met TMX-101, TMX-202, dragerstof of NaCl (placebo) gegeven. Ook hier 
waren geen tekenen van toxiciteit gezien en op de 12e dag werden de ratten geofferd 
voor histopathologische analyse van de blaas. Vergeleken met de placebogroepen 
waren er minder ratten met blaaskanker na behandeling met TMX-101 en TMX-202, al 
was dit niet statistisch significant. Het gebruikte rattenmodel vertoont een snelle 
ontwikkeling van agressieve blaastumoren, waardoor de het antitumor effect van de 
behandeling onvoldoende tot zijn recht kwam met twee blaasinstillaties. 
 
In hoofdstuk 4 beschrijven we een fase-1 klinische studie van blaasinstillaties met TMX-
101 in blaaskanker patiënten. Twee weken na de transurethrale resectie werd een serie 
van zes wekelijkse blaasinstillaties TMX-101 gegeven, in oplopende dosering. Vier 





Er werden lage, dosisafhankelijke systemische waarden gemeten na de 
blaasinstillaties. Er waren geen ernstige bijwerkingen. Wel waren er milde 
bijwerkingen bij bijna alle patiënten, meestal op urogenitaal gebied. Deze milde 
bijwerkingen zijn te vergelijken met BCG-instillaties. De ernstige bijwerkingen die soms 
na BCG worden gerapporteerd, worden in deze studie niet gezien, maar het aantal 
patiënten is te laag om daar een uitspraak over te kunnen doen.  
 
We hebben ook een ander type immunomodulator getest voor de behandeling van 
blaaskanker. In hoofdstuk 5 wordt een in vivo experiment beschreven van een 
instillatie met curcumine in combinatie met BCG in hetzelfde orthotope blaaskanker 
ratmodel als in hoofdstuk 3. Curcumine (kurkuma) is een onderdeel van kerrie. Het 
heeft zowel een immuunmodulerende werking als een antitumor-effect tegen het 
urotheelcelcarcinoom. Door curcumine met cyclodextrine (CDC) te verbinden, 
verbetert de oplosbaarheid, waardoor het een goede kandidaat voor blaasinstillaties 
is. Op meerdere humane en ratten blaaskanker cellijnen werd een antiproliferatief 
effect van CDC aangetoond in vitro. Voor het in vivo experiment werd de ratten een 
blaasinstillatie met tumorcellen gegeven waarmee tumorontwikkeling startte. Daarna 
werd een instillatie van CDC, BCG, een combinatie van CDC+BCG of NaCl, gegeven op 
dag 3, 7 en 10. Op dag 14 werden de ratten geofferd voor histopathologische 
beoordeling van de blaas. Al werd geen statistisch significant verschil gemeten, het 
percentage ratten met blaaskanker was lager na behandeling met CDC en de 
combinatie van CDC+BCG vergeleken met de placebogroep. BCG is de standaard 
aanvullende behandeling voor hoog-risico blaaskanker, maar interessant genoeg had 
BCG hier maar een matig effect op de blaastumoren, wat de agressiviteit van het 
model onderstreept. Het gegeven dat curcumine in dit model een effect lijkt te 
hebben, is veelbelovend. 
 
In hoofdstuk 6 evalueren we de overlappende immuunmodulerende 
werkingsmechanismen van BCG, TLR-7 agonisten en curcumine in het licht van de 
recente ontwikkelingen op het gebied van de Checkpoint-blokkade. De 
indrukwekkende ontwikkelingen op het gebied van checkpoint-blokkade voor de 
behandeling van het gemetastaseerd urotheelcelcarcinoom zal leiden tot het inzetten 
van deze middelen in een vroeger stadium van blaaskanker, dus ook bij het niet-





De belangrijkste uitdaging voor immunotherapie bij blaaskanker is het voorspellen van 
het succes, waardoor vooraf een individueel behandelplan kan worden opgesteld. Dit 
plan zal hoogstwaarschijnlijk een combinatie van verschillende immuunmodulatoren 
omvatten, dat resulteert in een lagere kans op recidief of progressie van het 
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Research data management 
 
In this thesis, one human study is presented (chapter 4). The trial was conducted in 
accordance with the principles of the Declaration of Helsinki. The medical and ethical 
review board Committee on Research Involving Human Subjects Region Arnhem-
Nijmegen, Nijmegen, the Netherlands has given approval to conduct this study. An 
audit trail was incorporated to provide evidence of the activities that has altered the 
original data. The privacy of the participants in this study is warranted by use of unique 
individual subject codes. The codelist to trace individual participants were accessible 
for the researcher gathering the data and the principal investigator. The codelist is 
stored separate from the study data. The data are written on paper case report forms 
(CRF’s). These are stored in the trial archive of the department of Urology, Radboud 
University Nijmegen Medical Centre, Nijmegen. Human material for laboratory tests 
was anonymized before analysis. Data from these tests were entered into GraphPad 
Prism 5.03 (GraphPad Software Inc, USA).  
The data and CRF’s will be saved for 15 years after termination of the study. Using 
these patient data in future research is only possible after a renewed permission by 
the patient as recorded in the informed consent. The datasets analyzed during these 
studies are available from the corresponding author on reasonable request. 
The animal studies (chapters 2,3 and 5) were approved by the Institutional Animal Care 
and Use Committee (IACUC), Committee for Animal Experiments (Radboud University 
Nijmegen Medical Centre, The Netherlands) and were in compliance with Dutch and 
European regulations. Data from the experiments described in chapter 2 and 5 were 
entered into GraphPad Prism database (version 5.03, GraphPad Software Inc, USA) 
and stored on the department server. Part of the data was exported to SPSS format 
for analysis. Data from the experiments described in chapter 3 were entered into SPSS 
format (SPSS Statistics, Version 21.0, IBM Corp., Armonk, USA) and stored on the 
department server.  
Published data generated or analyzed in this thesis are part of published articles and 






Het mooie aan een lang promotietraject is dat ik in al die jaren met veel mensen heb 
samengewerkt. Daarom een lijvig dankwoord. 
 
Prof. dr. J.A. Witjes, beste Fred. Ik liep al een paar maanden op de afdeling als keuze-
co-assistent en ik had bijna mijn opleiding afgerond. Je belde me op een ochtend dat 
je een plek voor me had als promovendus. Die middag had ik eigenlijk een 
sollicitatiegesprek voor een ANIOS-baan chirurgie. Jouw ‘advies’ was om dat gesprek 
als de bliksem af te bellen, omdat ik daar niks te zoeken had. Dit bleek een goed 
advies... 
In de jaren daarna heb je me vooral geleerd hoe belangrijk het is om naast 
onderzoeker ook een klinische dokter te zijn. Wetenschappelijke data worden 
daardoor omgetoverd tot relevante uitkomsten waarmee (toekomstige) patiënten 
gediend kunnen zijn. Of het nou op klinisch of wetenschappelijk vlak was door jouw 
supervisie gaf je me altijd eigen verantwoordelijkheid. Er zijn in die jaren, naast de 
resultaten in dit proefschrift, ook best wat onderzoeken gestrand. Door jouw 
langetermijnvisie (hele lange termijn, in dit geval) leidde dat niet tot opgeven. Bedankt 
daarvoor! 
 
Dr. E. Oosterwijk, beste Egbert. Als copromotor is jouw aandeel niet te onderschatten. 
Met je wetenschappelijke achtergrond en biomedische kennis kon jij (ogenschijnlijk 
makkelijk) waardevolle adviezen en tips geven waarmee ons werk verder kon. In de 
‘wandelgangen’ wist je waar iedereen mee bezig was, maar (h)erkende je ook de 
knelpunten. Dat is een bijzondere eigenschap waarmee je ook het verschil in 
achtergrond wist te overbruggen: ik wist immers niks van laboratoriumtechnieken of 
experimenten. Door jouw begeleiding kon ik de experimenten zelf uitvoeren. Ik snap 
nu dat je niet alleen naar resultaten moet kijken, maar dat het minstens zo belangrijk 
is hoe je tot die resultaten komt. Bedankt voor je begeleiding en de leuke tijd op het 






Dr. A.M. Leliveld-Kors, beste Annemarie. Bedankt voor je rol als copromotor in het 
Hoge Noorden. Toen ik voor de opleiding urologie was aangenomen in Groningen, 
was mijn promotieonderzoek nog niet af. Door jou en de collega’s in het UMCG werd 
erop gehamerd hoe belangrijk het was om het promotietraject af te ronden en kreeg 
ik de mogelijkheid een wetenschapsstage tijdens mijn opleiding te doen. Dat heeft het 
onderzoek vlot getrokken en dat is een van de redenen dat dit boekje er nu ligt. 
Daarnaast waren de dagen op de OK niet alleen gezellig om bij te kletsen maar heb je 
me veel operatieve vaardigheden bijgebracht, waar ik vandaag de dag nog veel aan 
heb. 
 
De leden van de Manuscriptcommissie: prof. dr. W.R. Gerritsen, prof. dr. R.J.A. van 
Moorselaar en dr. K. Hendricksen. Bedankt voor jullie bereidheid, tijd en inzet om het 
manuscript op inhoud te beoordelen.  
Kees, jouw eigen onderzoek stond aan de basis van veel van de experimenten en 
studies in dit proefschrift. Ik heb er veel aan gehad. 
 
Op deze plek wil ik ook de patiënten bedanken die hebben meegewerkt aan de 
wetenschappelijke studie in dit proefschrift en de hierop volgende studies. Uw 
deelname wordt erg op prijs gesteld en is bovenal onmisbaar in het onderzoek naar 
een betere behandeling voor u en voor toekomstige patiënten.  
 
Dr. C.A. Hulsbergen- van de Kaa, beste Christina. Bedankt voor de samenwerking. We 
hebben heel wat rattenblaasjes onder de microscoop beoordeeld. Dat heeft veel tijd 
gevergd, maar jouw expertise op het gebied van de uropathologie is essentieel 
geweest. Daarnaast heb je me meegenomen in de fascinerende wereld die je 
binnengaat wanneer je je oog aan het oculair van de microscoop zet.  
 
Beste Bianca en Kitty. Jullie ondersteuning op het dierenlab was onmisbaar, bedankt 
daarvoor. Ik heb waardering voor de respectvolle manier waarop jullie je werk doen. 
 
Alle collega’s van het Lab Experimentele Urologie waaronder Kees, Gerald, Jeanette, 
Dorien, Tilly, Frank, Onno, Paul, Daphne, Renate, Mirjam, Marion, Cindy, Elze, 
Maureen, Pim en Sander. Bedankt voor de mooie tijd op jullie afdeling, als onderdeel 





Er gebeurde meer op het lab dan alleen wetenschap: de gezellige koffiepauzes, uitjes, 
en besprekingen blijven me bij. Daarnaast wil ik ook iedereen bedanken die keer op 
keer basaal lab-werk heeft moeten uitleggen nadat jullie eerst hoofdschuddend en 
lachend hebben staan toekijken bij het afwegen, celkweken, coupes draaien, kleuren, 
centrifugeren etc. Ik weet nu wat experimenteel onderzoek inhoudt en ik weet ook 
dat goede collega’s hiervoor cruciaal zijn. In het bijzonder wil ik Kees bedanken: niet 
alleen voor je gezellige hulp bij de experimenten, maar ook voor de immer 
bemoedigende woorden “maar jíj wil promoveren?”.  
 
Prof. dr. J.A. Schalken, beste Jack. Bedankt dat ik onderdeel mocht zijn van het Lab 
Experimentele Urologie. Samen met alle collega’s heb je daar een hecht team 
gesmeed, waardoor ik er met plezier gewerkt heb. De koffiemomenten ’s ochtends 
waren belangrijk, want daar konden we de ontwikkelingen in formule 1, sport en 
andere belangrijke zaken even kort doorspreken. En oh ja, ook wetenschappelijke 
ontwikkelingen natuurlijk (komt dat laatste een beetje geloofwaardig over?). 
 
Martine en Harm, bedankt voor de mooie tijd. Ik trad toe tot het Blaaskankerteam. 
Jullie werkten me in op de Synergo-poli en brachten me zaken bij die belangrijk zijn 
voor het doen van wetenschappelijk onderzoek. Maar ik kijk toch ook terug op een 
mooie tijd buiten het werk om. Rick, jij maakte daar ook onderdeel van uit. Je had 
gelukkig niks met ‘het wereldje’ te maken, maar was wel op de hoogte van alle roddels 
en ontwikkelingen.  
Gisèle, ook jij vond je weg via Groningen naar Nijmegen. Ook al werkte jij aan een heel 
ander onderwerp, ik heb het ervaren als twee jaar samenwerken. We hebben goede 
inhoudelijke discussies gehad over het onderzoek, maar natuurlijk ook over muziek, 
lekkere drankjes en nutteloze weetjes. 
Samen met eerdergenoemde lieden hebben we met z’n allen veel mooie avonden 
gehad in het Laafje, Café Jos, ’t Haantje etc. etc. We hadden soms de mountainbike 
nodig om op mooie plekken in de omgeving te kunnen genieten (Merlijn, Duivelsberg, 
’t Zwaantje etc.). Toen Julia en later Volkert in beeld kwamen konden we mooi met z’n 
allen op mountainbiketochten door de Ardennen. Nu al vele jaren een traditie met 
bulkjes, lastminute quizvragen en een barrrbecuetje d’r bie. Oh ja, en mountainbiken.  






Rianne, jij versterkte het Blaaskankerteam: we hebben veel samengewerkt en veel 
gelachen. Naast een gezellige collega ben je ook een ambitieuze wetenschapper en 
uroloog. Ik heb veel bewondering voor je gedrevenheid en je gestructureerde manier 
van werken. En wie had gedacht dat jij naar het Hoge Noorden zou gaan? 
 
Max, ook jij kwam bij het Blaaskankerteam. Je had een tomeloze inzet en veel 
wetenschappelijke kennis. Los daarvan, hebben we veel gelachen om de 
muisbewegingen van muggendokters, speedboten en kachels.  
Bij het Blaaskankerteam horen ook de ‘synergo-zusters’: Annieke, Diana, Moniek en 
Wendy. Naast de nuttige blaaskankerbehandelingen die we samen verzorgden, waren 
het ook gezellige dagen op de poli. 
 
Ook wil ik hierbij alle andere promovendi van de urologie bedanken waarmee ik in de 
jaren heb samengewerkt: Dick, Stefanie, Ruben, Esther, Stijn, Minja, Frank, Tom, 
Siebren, Boy en Alexander.  
Ik zeg ‘samengewerkt’ en bedoel dat ook, maar dan ook aan de bar en op dansvloeren 
in Nijmegen en ver, vér daarbuiten.  
 
Sjaantje, Joop en Piet van ’t Haantje. Zonder jullie kroeg was dit proefschrift misschien 
enkele maanden eerder klaar geweest. Bedankt daarvoor. 
 
Urologen en arts-assistenten van het UMC st Radboud. Bedankt voor jullie 
collegialiteit en ondersteuning bij ‘de eerste stapjes’ binnen de urologie; voor mij 
waren het ‘stappen’. Jullie hebben me laten zien hoe leuk en fascinerend het vak 
urologie kan zijn. Het is bijzonder hoe de kliniek onlosmakelijk met de wetenschap 
verweven is. Dat levert op beide fronten betere resultaten. En zo nu en dan een 
proefschrift. 
 
De chirurgen en arts-assistenten heelkunde van het Martini Ziekenhuis Groningen wil 
ik bedanken voor de solide basis waarmee ik uiteindelijk uroloog geworden ben. Ik 







Beste Daphne, Jenneke, Willemijn, Hylco en Leon. Als urologen van het Martini 
Ziekenhuis Groningen wil ik jullie bedanken voor jullie belangrijke aandeel in mijn 
opleiding urologie en de fijne tijd: Bij jullie heb ik (kilo)meters gemaakt op de OK en de 
poli. Naast vakinhoudelijke kennis, hebben jullie me ook veel geleerd over het runnen 
van een praktijk. 
 
Urologen van het UMC Groningen; Igle Jan, Stijn, Josine, Rien, Bert, Benjamin, 
Annemarie, Mels, Emanuela en Boaz. Bedankt voor jullie rol als academische opleiders. 
De laagdrempeligheid, het geduld en de betrokkenheid maken dat ik met veel plezier 
en voldoening terugkijk op mijn opleiding. Nogmaals dank voor de mogelijkheid die 
jullie me boden voor het afschrijven van dit proefschrift.  
 
AIOS urologie: Oh oh, wat hebben we veel gezeurd. En daar vervolgens weer hard om 
gelachen. Het was erg gezellig. Het samenwerken met jullie heeft mijn opleiding tot 
een onvergetelijke tijd in Groningen gemaakt. De vroeg-Romeinse Woedeschaal heeft 
nog ergens een mooi plekje in de schuur.  
 
 
Er zijn ook mensen die niet direct hebben meegeholpen aan de studies en experimenten 
die in dit proefschrift staan. Zij hebben er op andere manieren aan bijgedragen dat het 
proefschrift tot stand kwam.  
Dit is een mooi moment jullie te bedanken. 
 
Lieve familie en vrienden. Jullie zijn enorm belangrijk voor mij. Soms spreken we elkaar 
vaak, soms wat minder. Maar we kunnen zo verder waar we gebleven waren. 
Er zijn dagen van gras en dagen van stro. Wat een goed gevoel dat ik altijd op jullie 
terug kan vallen. 
 
Jenny en Roelof. Vanaf het allereerste moment heb ik het gevoel gehad er bij te horen. 
Jullie zijn geweldige schoonouders. 
Stefan, Anne-Floor, Matthijs en Nick. Ik zat niet op voetbal, maar het is toch nog goed 






Sytze. Je betekent heel veel voor me. Als broers hebben we veel gemeen, nóg meer 
dan het lijkt. We hebben veel gave dingen gedaan. Maar ook in roerige tijden weten 
we wat we aan elkaar hebben. Het doet me denken aan wat we vroeger vaak zeiden: 
“twee broertjes”.  
 
Lieve ouders. Pa en Ma. Jullie stonden, en staan, werkelijk altijd voor ons klaar. Jullie 
waren er, bij alle stapjes en stappen die ik gemaakt heb. De onvoorwaardelijke steun 
en jullie positieve instelling zijn me dierbaar. Jullie hebben me geleerd wat écht 
belangrijk is. 
Nu ik zelf ouder ben, zie ik wat de uitdagingen kunnen zijn van een gezin, maar ervaar 
ik vooral hoe leuk het is. Als gezin kunnen genieten van grote en kleine dingen. Dat 
was vroeger zo en nu nog. Bedankt.  
 
Lieve Susanne. Toen ik in 2005 op sokken aan het Zuiderdiep stond, had ik nooit 
kunnen hopen dat het zo zou lopen. Sindsdien hebben we geweldige reizen gemaakt 
en grootse dingen gedaan. Maar het leukste met jou zijn de momenten die je zo weer 
zou vergeten omdat ze zo ‘normaal’ voor ons zijn. Maar het is niet normaal.  
De bruiloft was geweldig. Maar het kon blijkbaar nóg beter. Namelijk als gezin. Met 
jullie is het leven goed. Bedankt voor je hulp en voor je steun.  
 
Mats. Het mooiste moment in mijn leven begon op een nazomerdag in 2018 en dat 
moment duurt maar voort. Onze talloze fietsritjes langs de IJssel, langs de molen en 
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